var title_f6_5_6224="Gait cycle";
var content_f6_5_6224=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F53103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F53103&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    Gait cycle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The gait cycle has four phases: Heel-strike to foot-flat (contact), foot-flat to heel-off (mid-stance), heel-off to toe-off (propulsion), and toe-off to heel-strike (swing).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6224=[""].join("\n");
var outline_f6_5_6224=null;
var title_f6_5_6225="Complete cuff tear MR";
var content_f6_5_6225=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F51905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F51905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Complete rotator cuff tear on magnetic resonance imaging",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 347px; height: 251px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Coronal oblique T2 weighted fat supressed image shows full thickness supraspinatus tendon tear with tendon retraction (red arrow) and joint effusion extending to the subacromial/subdeltoid bursa.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Douglas H Brown, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6225=[""].join("\n");
var outline_f6_5_6225=null;
var title_f6_5_6226="Skin stapling";
var content_f6_5_6226=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F69979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F69979&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 528px\">",
"   <div class=\"ttl\">",
"    Placement of skin staples",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 508px; height: 596px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Place the stapler perpendicular to and centered over the wound while everting the wound edges with forceps (preferable, figure A above) or thumb and forefinger. While pinching the edges of the wound together, gently squeeze the staple handle to eject the staple into the skin. If the stapler does not automatically release, then release the staple from the stapler by pulling the stapler back. When properly placed, the crossbar of the staple is elevated a few millimeters above the skin surface (figure B above).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6226=[""].join("\n");
var outline_f6_5_6226=null;
var title_f6_5_6227="Hepatic adenoma gross";
var content_f6_5_6227=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F72131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F72131&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Hepatic adenoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 302px; height: 335px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gross sectioned pathological specimen of a resected pedunculated hepatic adenoma measuring &gt;6 cm in diameter. The adenoma shows the typically tan fleshy appearance of an adenoma with no capsule. There is no evidence of hemorrhage or necrosis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Imad Nasser, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6227=[""].join("\n");
var outline_f6_5_6227=null;
var title_f6_5_6228="Ganciclovir (ophthalmic): Drug information";
var content_f6_5_6228=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Ganciclovir (ophthalmic): Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?40/53/41811?source=see_link\">",
"    see \"Ganciclovir (ophthalmic): Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/58/6052?source=see_link\">",
"    see \"Ganciclovir (ophthalmic): Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F8106936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Vitrasert&reg;;",
"     </li>",
"     <li>",
"      Zirgan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F8106941\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antiviral Agent, Ophthalmic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F8107015\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CMV retinitis:",
"     </b>",
"     <i>",
"      Intravitreal implant:",
"     </i>",
"     One implant for 5- to 8-month period; following depletion of ganciclovir, as evidenced by progression of retinitis, implant may be removed and replaced",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Herpetic keratitis:",
"     </b>",
"     <i>",
"      Ophthalmic gel:",
"     </i>",
"     Apply 1 drop in affected eye 5 times/day (approximately every 3 hours while awake) until corneal ulcer heals, then 1 drop 3 times/day for 7 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F8107014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/58/6052?source=see_link\">",
"      see \"Ganciclovir (ophthalmic): Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      CMV retinitis:",
"     </b>",
"     <i>",
"      Intravitreal implant:",
"     </i>",
"     Children &ge;9 years: Refer to adult dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Herpetic keratitis:",
"     </b>",
"     <i>",
"      Ophthalmic gel:",
"     </i>",
"     Children &ge;2 years; Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F8107016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15896338\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15896339\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer's labeling. However, dosage adjustment unlikely due to low systemic absorption.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F8107063\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, ophthalmic [drops]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Zirgan&reg;: 0.15% (5 g) [contains benzalkonium chloride]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Implant, intravitreal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vitrasert&reg;: 4.5 mg (1s) [released gradually over 5-8 months]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F8106939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F16342441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F8106954\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intravitreal implant: Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ophthalmic gel: Treatment of acute herpetic keratitis (dendritic ulcers)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F8106933\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Ganciclovir may be confused with acyclovir",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F8106977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Intravitreal implant",
"     </b>",
"     : &gt;10%: Ocular: Visual acuity decreased (&ge;3 lines; temporary).",
"     <b>",
"      Note:",
"     </b>",
"     Adverse reactions are likely a result of the surgical implant procedure.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Ophthalmic gel:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &gt;10%: Ocular: Blurred vision (60%), irritation (20%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     1% to 10%: Ocular: Punctate keratitis (5%), conjunctival hyperemia (5%)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F8106961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Intravitreal implant: Hypersensitivity to ganciclovir, acyclovir, or any component of the formulation; clinical conditions contraindicating intraocular surgery, such as external infection or severe thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ophthalmic gel: There are no contraindications listed in the manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F8106962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Intravitreal implant: Immediate and temporary decrease in visual acuity will be seen following implantation. The implant provides localized therapy to the implanted eye and does not provide treatment for systemic CMV disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ophthalmic gel: Contact lenses should not be worn during therapy or in any patient with herpetic keratitis. Gel is intended for topical ophthalmic use only.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299386\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F8106981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F8106956\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F8106957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were observed in animal reproduction studies conducted with systemic ganciclovir. Based on animal studies, a U.S. Boxed Warning has been added to the labeling of the systemic product and effective contraception is recommended in males and females using systemic therapy. The amount of ganciclovir available systemically following topical application of the Zirgan&reg; ophthalmic gel is significantly less in comparison I.V. doses (0.1%). Vitrasert&reg; intravitreal implant contains only 4.5-6.4 mg of ganciclovir and is released locally in the vitreous from the implant. Ophthalmic formulations should be used only if potential benefit justifies the risk to the fetus.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F8106959\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/not recommended",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F8106960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Due to the carcinogenic and teratogenic effects observed in animal studies with systemic ganciclovir, the possibility of adverse events in a nursing infant is considered likely. Therefore, nursing should be discontinued during therapy. In addition, the CDC recommends",
"     <b>",
"      not",
"     </b>",
"     to breast-feed if diagnosed with HIV to avoid postnatal transmission of the virus.",
"    </p>",
"    <p style=\"text-indent:0em;margin-left:0em;margin-top:2em;\">",
"     The amount of ganciclovir available systemically following ophthalmic application is not known. Caution should be used with administration of the ophthalmic gel. Due to adverse events in nursing animals, the manufacturer of the intravitreal implant recommends that breast feeding be discontinued during therapy; in addition, the CDC recommends",
"     <b>",
"      not",
"     </b>",
"     to breast-feed if diagnosed with HIV to avoid postnatal transmission of the virus.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322183\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Zirgan Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.15% (5 g): $241.55",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Implant",
"     </b>",
"     (Vitrasert Intraocular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4.5 mg (1): $19200.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F8107032\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmologic exams",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F8106999\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ganciclovir is phosphorylated to a substrate which competitively inhibits the binding of deoxyguanosine triphosphate to DNA polymerase resulting in inhibition of viral DNA synthesis",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F10276580\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Absorption: Ophthalmic gel: Negligible systemic absorption (0.1% in comparison to I.V. doses)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Kaplan JE, Benson C, Holmes KH, et al, &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-4):1-207.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/5/6228/abstract-text/19357635/pubmed\" id=\"19357635\" target=\"_blank\">",
"        19357635",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9138 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-221.179.173.170-794AB5B1AF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6228=[""].join("\n");
var outline_f6_5_6228=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106936\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106941\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107015\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107014\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107016\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896338\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15896339\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107063\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106939\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16342441\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106954\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106933\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106977\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106961\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106962\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299386\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106981\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106956\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106957\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106959\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106960\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322183\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8107032\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F8106999\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10276580\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9138\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9138|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?40/53/41811?source=related_link\">",
"      Ganciclovir (ophthalmic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/58/6052?source=related_link\">",
"      Ganciclovir (ophthalmic): Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?24/3/24630?source=related_link\">",
"      Ganciclovir (systemic): Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?30/18/31012?source=related_link\">",
"      Ganciclovir (systemic): Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/42/13990?source=related_link\">",
"      Ganciclovir (systemic): Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_5_6229="Demeclocycline: Pediatric drug information";
var content_f6_5_6229=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Demeclocycline: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=see_link\">",
"    see \"Demeclocycline: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/49/38676?source=see_link\">",
"    see \"Demeclocycline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1046937\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antibiotic, Tetracycline Derivative",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1046930\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=see_link\">",
"      see \"Demeclocycline: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;8 years: 8-12 mg/kg/day divided every 6-12 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 150 mg 4 times/day or 300 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Uncomplicated gonorrhea: 600 mg stat, 300 mg every 12 hours for 4 days (3 g total)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SIADH: Initial: 600-1200 mg/day or 13-15 mg/kg/day divided every 6-8 hours; then decrease to 600-900 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     Dose and/or frequency should be modified in response to the degree of renal impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Not recommended for use",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F157414\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 150 mg, 300 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F157398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1046940\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer 1 hour before or 2 hours after food or milk with plenty of fluids; do not administer with food, milk, dairy products, antacids, zinc, or iron supplements",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1046939\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible bacterial infections (acne, gonorrhea, pertussis, chronic bronchitis, and urinary tract infections) caused by both gram-negative and gram-positive organisms; treatment of chronic syndrome of inappropriate antidiuretic hormone (SIADH) secretion",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F157475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Pericarditis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Bulging fontanels (infants), dizziness, headache, pseudotumor cerebri (adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Angioedema, anogenital inflammatory lesions (with monilial overgrowth), erythema multiforme, erythematous rash, exfoliative dermatitis (rare), maculopapular rash, photosensitivity, pigmentation of skin, Stevens-Johnson syndrome (rare), urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Microscopic discoloration of thyroid gland (brown/black), nephrogenic diabetes insipidus, thyroid dysfunction (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Anorexia, diarrhea, dysphagia, enterocolitis, esophageal ulcerations, glossitis, nausea, pancreatitis, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Balanitis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Eosinophilia, neutropenia, hemolytic anemia, thrombocytopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Hepatitis (rare), hepatotoxicity (rare), liver enzymes increased, liver failure (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Myasthenic syndrome, polyarthralgia, tooth discoloration (children &lt;8 years, rarely in adults)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Visual disturbances",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Otic: Tinnitus",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Acute renal failure, BUN increased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Pulmonary infiltrates",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylaxis, anaphylactoid purpura, fixed drug eruptions (rare), lupus-like syndrome, superinfection, systemic lupus erythematosus exacerbation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1046944\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to demeclocycline, tetracyclines, or any component",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1046929\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with impaired renal or hepatic function; modify dose in patients with renal impairment",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1046928\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Photosensitivity reactions, characterized as severe burns of exposed surfaces, occur frequently with this drug; avoid prolonged exposure to sunlight; do not use tanning equipment. Do not administer to children &lt;8 years of age; use of tetracyclines during tooth development (last half of pregnancy, infancy, and children &lt;8 years of age) may cause permanent discoloration of the teeth and enamel hypoplasia. Do not administer to pregnant women; use of tetracyclines in pregnant women may result in retardation of bone growth and skeletal development of the fetus. Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment. Avoid use when possible in patients with hepatic disease. Demeclocycline may cause a reversible, dose-related diabetes insipidus syndrome. Use of outdated tetracyclines has caused a Fanconi-like syndrome.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299132\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F157407\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BCG: Antibiotics may diminish the therapeutic effect of BCG.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bile Acid Sequestrants: May decrease the absorption of Tetracycline Derivatives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bismuth: May decrease the serum concentration of Tetracycline Derivatives. Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bismuth Subsalicylate: May decrease the serum concentration of Tetracycline Derivatives. Management: Consider dosing tetracyclines 2 hours before, or 6 hours after, bismuth subsalicylate. The need to separate doses during Helicobacter pylori eradication regimens is questionable.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Salts: May decrease the serum concentration of Tetracycline Derivatives. Management: If coadministration of oral calcium with oral tetracyclines can not be avoided, consider separating administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Desmopressin: Demeclocycline may diminish the therapeutic effect of Desmopressin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iron Salts: May decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ferric Gluconate; Ferumoxytol; Iron Dextran Complex; Iron Sucrose.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lanthanum: May decrease the serum concentration of Tetracycline Derivatives. Management: Administer oral tetracycline antibiotics at least two hours before or after lanthanum.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Salts: May decrease the absorption of Tetracycline Derivatives. Only applicable to oral preparations of each agent.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mipomersen: Tetracycline Derivatives may enhance the hepatotoxic effect of Mipomersen.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Multivitamins/Minerals (with ADEK, Folate, Iron): May decrease the serum concentration of Tetracycline Derivatives. Management: If coadministration of a polyvalent cation-containing multivitamin with oral tetracyclines can not be avoided, separate administration of each agent by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Neuromuscular-Blocking Agents: Tetracycline Derivatives may enhance the neuromuscular-blocking effect of Neuromuscular-Blocking Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Penicillins: Tetracycline Derivatives may diminish the therapeutic effect of Penicillins.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinapril: May decrease the serum concentration of Tetracycline Derivatives. Management: Separate doses of quinapril and oral tetracycline derivatives by at least 2 hours in order to reduce the risk of interaction. Monitor for reduced efficacy of the tetracycline if these products are used concomitantly.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Retinoic Acid Derivatives: Tetracycline Derivatives may enhance the adverse/toxic effect of Retinoic Acid Derivatives. The development of pseudotumor cerebri is of particular concern.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Adapalene; Alitretinoin; Tretinoin (Topical).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Strontium Ranelate: May decrease the serum concentration of Tetracycline Derivatives. Management: In order to minimize any potential impact of strontium ranelate on tetracycline antibiotic concentrations, it is recommended that strontium ranelate treatment be interrupted during tetracycline therapy.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Tetracycline Derivatives. Management: Administer the tetracycline derivative at least 2 hours prior to sucralfate in order to minimize the impact of this interaction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 24 hours after cessation of antibacterial agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Tetracycline Derivatives may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zinc Salts: May decrease the absorption of Tetracycline Derivatives. Only a concern when both products are administered orally.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Zinc Chloride.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1046946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food, milk, milk formulas, dairy products, and iron decrease absorption of demeclocycline",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F157410\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     D (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F157423\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Tetracyclines, including demeclocycline, cross the placenta and accumulate in developing teeth and long tubular bones. Tetracyclines may discolor fetal teeth following maternal use during pregnancy; the specific teeth involved and the portion of the tooth affected depends on the timing and duration of exposure relative to tooth calcification. As a class, tetracyclines are generally considered second-line antibiotics in pregnant women and their use should be avoided (Gibbons, 1960; Mylonas, 2011).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1046936\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     CBC, renal and hepatic function tests, I &amp; O, urine output, serum sodium; observe for changes in bowel frequency",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1046927\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits protein synthesis by binding with the 30S ribosomal subunits and preventing the binding of transfer RNA to those ribosomes of susceptible bacteria; may also cause alterations in the cytoplasmic membrane",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1046942\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onset of action for diuresis in SIADH: Within 5 days",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1046943\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: &sim;60% to 80% of dose absorbed from the GI tract; food and dairy products reduce absorption by 50% or more",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Distributes into pleural fluid, bronchial secretions, sputum, prostatic and seminal fluids, and to body tissues; crosses into breast milk",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 36% to 91%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Small amounts metabolized in the liver to inactive metabolites; enterohepatically recycled",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: Adults: 10-17 hours (prolonged with reduced renal function)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Oral: Within 3-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Excreted as unchanged drug (42% to 50%) in urine and 31% in feces",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1046935\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/49/38676?source=see_link\">",
"      see \"Demeclocycline: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May cause photosensitivity reactions (eg, exposure to sunlight may cause severe sunburn, skin rash, redness, or itching); avoid exposure to sunlight and artificial light sources (sunlamps, tanning booth/bed); wear protective clothing, wide-brimmed hats, sunglasses, and lip sunscreen (SPF &ge;15); use a sunscreen [broad-spectrum sunscreen or physical sunscreen (preferred) or sunblock with SPF &ge;15]; contact physician if reaction occurs. May cause dizziness, vertigo, lightheadedness, blurred vision and impair ability to perform activities requiring mental alertness or physical coordination; may discolor fingernails. Avoid taking dosages at bedtime to reduce risk of esophageal ulceration",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abdi EA and Bishop S, &ldquo;The Syndrome of Inappropriate Antidiuretic Hormone Secretion With Carcinoma of the Tongue,&rdquo;",
"      <i>",
"       Med Pediatr Oncol",
"      </i>",
"      , 1988, 16(3):210-5.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/5/6229/abstract-text/3132592/pubmed\" id=\"3132592\" target=\"_blank\">",
"        3132592",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      De Troyer AD, &ldquo;Demeclocycline. Treatment for Syndrome of Inappropriate Antidiuretic Hormone Secretion,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1977, 237(25):2723-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?6/5/6229/abstract-text/194065 /pubmed\" id=\"194065 \" target=\"_blank\">",
"        194065",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13209 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-7AD06D259D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6229=[""].join("\n");
var outline_f6_5_6229=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046937\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046930\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157414\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157398\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046940\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046939\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157475\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046944\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046929\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046928\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299132\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157407\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046946\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157410\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F157423\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046936\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046927\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046942\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046943\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1046935\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13209\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13209|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?10/4/10310?source=related_link\">",
"      Demeclocycline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/49/38676?source=related_link\">",
"      Demeclocycline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_5_6230="Renal pathology of early diffuse mesangial sclerosis";
var content_f6_5_6230=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F77219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F77219&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Renal pathology of early diffuse mesangial sclerosis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 346px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pathologic specimen from a patient with diffuse mesangial sclerosis demonstrating the fibrillar increase in mesangial matrix. The capillary walls are lined by hypertrophied podocytes.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6230=[""].join("\n");
var outline_f6_5_6230=null;
var title_f6_5_6231="Acquired arteriovenous fistula of the lower extremity";
var content_f6_5_6231=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acquired arteriovenous fistula of the lower extremity",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/5/6231/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/5/6231/contributors\">",
"     Emile R Mohler III, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/5/6231/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/5/6231/contributors\">",
"     Denis L Clement, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/5/6231/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/5/6231/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/5/6231/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/5/6231/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/5/6231/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 14, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arteriovenous fistulas (AVFs) are abnormal connections between the arterial and venous system that bypass the normal anatomic capillary beds. They can be located anywhere in the body, single or multiple, and congenital or acquired (eg, trauma) (",
"    <a class=\"graphic graphic_table graphicRef68547 \" href=\"UTD.htm?23/51/24379\">",
"     table 1",
"    </a>",
"    ). Acquired AVF of the lower extremity is by far the most commonly occurring AVF due to the frequency of the groin as a site for percutaneous arterial and venous access.",
"   </p>",
"   <p>",
"    AVFs of the lower extremity will be reviewed here. AVFs affecting other sites, such as the brain and lungs, and patent ductus arteriosus are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=see_link\">",
"     \"Vascular malformations of the central nervous system\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27656?source=see_link\">",
"     \"Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=see_link\">",
"     \"Clinical manifestations and diagnosis of patent ductus arteriosus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94699883\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Throughout the body, arteries and veins are closely associated with one another. Most arteries have laterally paired veins which have intervenous communications (ie, venae comitantes) that pass anterior or posterior to the artery. Larger arteries may have one closely associated vein, or the second vein may be diminutive in size. Venous tributaries also often pass anterior to the artery before emptying into a larger vein.",
"   </p>",
"   <p>",
"    Any device, implement or projectile that traverses an artery and vein has the potential to lead to AVF. The direction may be from artery to vein or vein to artery. During percutaneous access, lateral or medial needle deviation or needle placement through vena comitantes or venous tributary can lead to combined artery and vein puncture. In many cases, the errant needle placement is noticed (eg, dark blood during arterial puncture, pulsatile blood during venous puncture) and the needle is withdrawn. In most cases, the communication between the artery and vein will spontaneously seal. However, in the face of certain risk factors, the communication between the artery and vein may not seal and AVF will result.",
"   </p>",
"   <p>",
"    Long-standing AVFs can lead to limb edema, high-output cardiac failure, or aneurysmal degeneration of the artery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Large common femoral AVFs can result in hemodynamic shifts due to the diversion of blood from the high resistance arterial circulation to the low resistance venous circuit. The shunt increases venous volume and pressure and decreases peripheral vascular resistance. The ensuing increase in stroke volume and heart rate may lead to a dramatic rise in cardiac output. Another consequence of high flow AVF is reduced blood flow to the lower extremity, which, in the face of pre-existing peripheral artery disease (PAD), can lead to the onset or worsening of lower extremity ischemic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Clinical evaluation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94700565\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Risk factors for iatrogenic arteriovenous fistula include female gender, hypertension, anticoagulation or antifibrinolytic therapy, left-sided, low or multiple punctures, increased body mass index and advanced patient age [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/7-12\">",
"     7-12",
"    </a>",
"    ]. Operator-dependent factors that can be modified include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Low groin puncture &ndash; Low groin puncture is more likely to access the deep or superficial femoral artery just distal to the common femoral artery bifurcation. The profunda femoris vein passes between the superficial femoral artery and the profunda femoris artery to drain into the common femoral vein. Punctures to the proximal SFA are particularly vulnerable to causing AVF because the needle tip frequently punctures the underlying profunda vein. &nbsp;(See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36024?source=see_link\">",
"       \"Placement of femoral venous catheters\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Sheath placement &ndash; Dilation of the tract between an artery and vein reduces the likelihood that the communication will close. The larger the sheath size, the greater the risk for AVF.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the lower extremity, AVF is most commonly iatrogenic, primarily due to arterial access in the groin for percutaneous cardiovascular procedures. Although less common, iatrogenic AVF can result from endoluminal manipulation. Devices that have led to AVF include endovenous laser for saphenous ablation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/13\">",
"     13",
"    </a>",
"    ], percutaneous directional atherectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/14\">",
"     14",
"    </a>",
"    ], and devices used for re-entry during subintimal angioplasty [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/15\">",
"     15",
"    </a>",
"    ]. Penetrating trauma can cause AVF anywhere in the extremity depending upon the trajectory of the missile or implement. Rarely, AVF may be due to central venous access procedures.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94699890\">",
"    <span class=\"h2\">",
"     Percutaneous groin access",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of AVF following percutaneous groin access varies from 0.006 to 0.88 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/2,7,8,16,17\">",
"     2,7,8,16,17",
"    </a>",
"    ]. Distal groin puncture is the main cause of post-catheterization AVFs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/7\">",
"     7",
"    </a>",
"    ]. The incidence is higher in therapeutic compared with diagnostic catheterization (0.87 versus 0.15 percent in one report) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/10,12\">",
"     10,12",
"    </a>",
"    ]. The presence of one or more risk factors increases the potential that combined artery and venous puncture will result in a clinically important AVF. (See",
"    <a class=\"local\" href=\"#H94700565\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Although the use of arterial closure devices may reduce the rates for femoral pseudoaneurysm, rates for AVF have not changed [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/18\">",
"     18",
"    </a>",
"    ]. Hemorrhagic complications of cardiovascular intervention are discussed elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/7-9,19\">",
"     7-9,19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=see_link\">",
"     \"Complications of diagnostic cardiac catheterization\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94697664\">",
"    <span class=\"h2\">",
"     Trauma",
"    </span>",
"    &nbsp;&mdash;&nbsp;AVFs may also result from penetrating injury to the lower extremity including stab wounds, gunshot and shotgun injuries [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/20\">",
"     20",
"    </a>",
"    ]. Although there are no large epidemiologic studies on the prevalence of traumatic AVFs, the incidence may be rising due to the increasing number of firearm injuries over the last 30 years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12186?source=see_link\">",
"     \"Severe extremity injury in the adult patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following any cardiovascular intervention, the puncture site should be carefully evaluated and a complete lower extremity vascular examination should assess for adequacy of the pulses; ideally, the pulses are compared with the pre-interventional vascular examination. Any findings suggestive of a vascular complication warrant further investigation.",
"   </p>",
"   <p>",
"    Following combined artery and vein puncture, almost all AVFs are initially clinically silent. When symptoms occur, the time of onset ranges from two days to several months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/1\">",
"     1",
"    </a>",
"    ]. Symptoms suggestive of AVF include abnormal sensation (eg, vibration) in the groin, and fatigue, and new onset or worsened lower extremity ischemia.",
"   </p>",
"   <p>",
"    The clinical diagnosis of AVF is made by palpation and auscultation of the affected vessel which may demonstrate a machinery-like murmur, bruit, hematoma or pulsatile mass. The patient may exhibit lower extremity edema [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinical conditions that are related to lower extremity AVF include deep venous thrombosis, symptoms of nerve compression and new onset or worsened varicose veins [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/2,10,22\">",
"     2,10,22",
"    </a>",
"    ]. The diagnosis of these conditions is discussed in separate topic reviews.",
"   </p>",
"   <p>",
"    The most significant condition related to AVF is high-output heart failure, which has been estimated to occur after 0.01 to 0.02 percent of cardiac catheterizations [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/1\">",
"     1",
"    </a>",
"    ]. The clinical diagnosis of high output heart failure is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=see_link\">",
"     \"High-output heart failure\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94697943\">",
"    <span class=\"h2\">",
"     Noninvasive vascular laboratory examination",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94697718\">",
"    <span class=\"h3\">",
"     Duplex ultrasonography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Duplex ultrasound is the current diagnostic test of choice for evaluating patients with suspected AVFs. On ultrasound, high frequency, low resistance flow is typical of AVFs with a mosaic color pattern on duplex. Often the specific artery and vein involved can be identified (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58366 \" href=\"UTD.htm?1/14/1249\">",
"     image 1",
"    </a>",
"    ). Duplex ultrasonography also provides a potential means of treatment. (See",
"    <a class=\"local\" href=\"#H94697830\">",
"     'Ultrasound-guided compression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Greater awareness of postcatheterization complications and the ease of diagnosis by duplex ultrasonography have reduced the incidence of symptomatic lower extremity AVFs. However, ultrasound scans are not routinely performed following instrumentation unless a large hematoma or bruit is present. For patients identified with an AVF, a follow-up ultrasound study is obtained after about a month to evaluate whether it has closed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94697951\">",
"    <span class=\"h3\">",
"     ABI and lower extremity physiologic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with known peripheral artery disease (PAD), or those with new onset symptoms of PAD, should be evaluated with physiologic vascular studies to evaluate the hemodynamic impact of the AVF on the distal lower extremity circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94699039\">",
"    <span class=\"h3\">",
"     Arteriography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although not considered a first-line diagnostic modality, computed tomographic angiography is frequently performed in trauma patients and may demonstrate an AVF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/23\">",
"     23",
"    </a>",
"    ]. On conventional arteriography, the AVF appears as a blush with rapid filling of the adjacent deep vein. Arteriography may potentially lead to endovascular treatment in symptomatic patients. (See",
"    <a class=\"local\" href=\"#H94697837\">",
"     'Endovascular repair'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most small asymptomatic AVFs thrombose spontaneously and thus should be observed. Treatment is indicated for patients who develop symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/16,22\">",
"     16,22",
"    </a>",
"    ]. Surgical repair is the standard approach, but ultrasound-guided compression (UGC) and percutaneous techniques are alternative treatments if anatomically feasible, especially for patients who may not tolerate any degree of bleeding, have a hostile groin due to excessive scar tissue, or who have a prohibitive risk for anesthesia.",
"   </p>",
"   <p>",
"    In a study of 81 lower extremity AVFs, 57 patients who did not require immediate surgical repair were followed conservatively. Of these, 46 (81 percent) had spontaneous resolution of the AVF at a mean of 23 days. The remaining 11 required surgical closure at a mean of four months [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94697830\">",
"    <span class=\"h2\">",
"     Ultrasound-guided compression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultrasound-guided compression (UGC) to effect closure of AVF refers to a technique in which an ultrasound probe is placed over the AVF to provide compression of sufficient force to abolish flow through the fistula without unduly reducing distal perfusion. The duration of compression is usually about 10 minutes. Ultrasound-guided compression can be attempted when the AVF is initially identified. In observational studies of UGC, up to one-third of patients with AV fistula may avoid the need for other forms of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/3,21,24,25\">",
"     3,21,24,25",
"    </a>",
"    ]. However, the groin is often too tender to allow compression; if the procedure becomes painful, it should be abandoned. Failure of UGC is frequent and is because the fistula track is too short or the AV fistula is too large to be compressed effectively by the transducer. Chronic AVFs (&gt;2 to 3 weeks) rarely respond to compression. Ongoing anticoagulation also decreases success rates of UGC [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/4,26\">",
"     4,26",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1229237943\">",
"    <span class=\"h2\">",
"     Repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Repair of AVF is indicated for patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical symptoms related to the AVF",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Steal syndrome causing claudication or distal limb ischemia",
"     </li>",
"     <li>",
"      Significant edema or venous insufficiency due to venous hypertension",
"     </li>",
"     <li>",
"      Heart failure due to a high-flow fistula",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progressive enlargement under ultrasound surveillance",
"     </li>",
"     <li>",
"      Large AVF following stab, gunshot or other projectile injury",
"     </li>",
"     <li>",
"      Iatrogenic AVFs that do not seal spontaneously",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1229237957\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgery for AVF that is not associated with hematoma or pseudoaneurysm is relatively straightforward. The procedure can be performed under general or neuraxial anesthesia or peripheral nerve block depending upon patient and surgeon preference and underlying anesthetic risk. Just prior to the procedure, duplex ultrasound should be performed to confirm that the AVF is still patent and to mark its position on the skin.",
"   </p>",
"   <p>",
"    In general, an incision is made overlying the site of the fistula as identified by duplex ultrasound or other imaging modality. It is important to note that the superficial veins of the skin and subcutaneous tissues are pressurized, and care must be taken to avoid uncontrolled transection. These vessels should be taken between clamps, and carefully divided and ligated to minimize the potential for blood loss. The artery and vein proximal to the site are dissected free of the surrounding tissue and vascular control obtained with hemostatic loops. The artery is dissected from proximal to distal until the fistula is identified. The presence of localized inflammation usually identifies the site of the fistula. For acute AVFs, inflammation is typically minimal. During dissection of the fistula, care must be taken to avoid stripping the adventitia from the artery, which weakens the arterial wall and complicates the repair. Until the AVF is taken down, the vein is pressurized and can easily tear.",
"   </p>",
"   <p>",
"    Once the arteriovenous connection is divided, direct pressure is usually all that is needed to control bleeding from the venous wall defect. The arterial wall defect can be controlled with pressure, or arterial hemostatic loops or clamps. Each defect is sutured closed with permanent suture; often only a single stitch in each is needed. Once the repair is complete, control on the artery is released and the pulse distal to the repair site evaluated with a Doppler.",
"   </p>",
"   <p>",
"    Complications of surgical AVF repair include hemorrhage due to venous hypertension and groin infection. In some cases, the AVF may be difficult to identify [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/12,27\">",
"     12,27",
"    </a>",
"    ]. Under this circumstance, intraoperative duplex ultrasound may help identify the fistula and its origin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94697837\">",
"    <span class=\"h2\">",
"     Endovascular repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endovascular repair of AVF is an alternative treatment for those patients deemed too high risk for anesthesia, those with a hostile groin due to excessive scar tissue, or who may not tolerate the consequences of hemorrhage that may occur with surgical control of the AV fistula. Percutaneous interventions, including covered stent placement or embolization techniques, may be effective as an alternative to surgical repair. However, these interventions require arterial puncture, typically in the contralateral common femoral artery, which may also develop complications.",
"   </p>",
"   <p>",
"    Covered stent implantation is an attractive treatment option for AVFs. The ability to use this technology depends upon the location of the fistula, the presence of underlying peripheral artery disease and the overall medical status of the patient.",
"   </p>",
"   <p>",
"    The common femoral artery is a less suitable location for a stent due to the potential for stent deformation and fracture from hip flexion and rotation. Stent placement at this location may also preclude the use of the site for future femoral access. Iatrogenic AVF that originates from the proximal superficial femoral or deep femoral artery may be more amenable to percutaneous repair because these sites are less likely to be mechanically distorted; however, because the deep femoral vessels are smaller in caliber, it may be at risk for stent-graft thrombosis. Short covered superficial femoral artery stents placed appear to have adequate patency.",
"   </p>",
"   <p>",
"    Reported patency rates for stent-graft repair of AVF range between 88 percent and 100 percent at follow-up (eight months to one year) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/27-29\">",
"     27-29",
"    </a>",
"    ]. In one study that evaluated 53 patients with catheter-related complications, technical success for stent placement or coil embolization was achieved in 89 percent of patients; closure of the AVF was documented in all treated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/24\">",
"     24",
"    </a>",
"    ]. However, four late stent occlusions occurred between three and six months follow-up. Similar findings were noted in a series nine patients with AVF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/28\">",
"     28",
"    </a>",
"    ]. Successful stent placement was achieved in 90 percent, but two major complications were observed.",
"   </p>",
"   <p>",
"    Although long-term follow-up is limited, percutaneous coil or N-butyl-cyanoacrylate embolization are alternative endovascular treatment approaches, provided the connecting channel of the AVF can be appropriately imaged and is of sufficient length [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/24,30\">",
"     24,30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94697906\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for AV fistula following repair is excellent. Physiologic derangements reverse immediately after the fistula is closed. In one report, for example, the mean cardiac output decreased from 12.2",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    to 5.4",
"    <span class=\"nowrap\">",
"     L/min",
"    </span>",
"    after surgical repair of the AVFs [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6231/abstract/31\">",
"     31",
"    </a>",
"    ]. For patients with underlying peripheral artery disease, the increase in arterial flow to the lower extremity following fistula repair can be expected to return the patient to baseline functional status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H94697279\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Arteriovenous fistulas (AVFs) are abnormal connections between the arterial and venous system. They may be congenital or acquired, may be single or multiple, and can affect any organ in the body but are commonly found in the extremities. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common etiology of lower extremity AVF is iatrogenic, primarily the result of percutaneous cardiovascular diagnostic procedures or interventions. AVFs may also result from penetrating lower extremity traumatic injury, the prevalence of which may be rising due to the increasing number of firearm injuries. (See",
"      <a class=\"local\" href=\"#H94699883\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptoms suggestive of AVF include fatigue, new onset or worsened lower extremity ischemia, or abnormal sensation (eg, vibration) in the groin. Clinical signs include a machinery-like murmur or bruit in the groin, hematoma, pulsatile mass, lower extremity edema, deep vein thrombosis or the new onset high output cardiac failure. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Duplex ultrasonography is indicated in any patient with signs and symptoms suspicious for AVF. High frequency, low resistance flow, and a mosaic color pattern are typical duplex findings of AVFs. Often, the specific artery and vein involved can be identified. On arteriography, the AVF appears as a blush with rapid filling of the adjacent deep vein. For patients with symptoms of lower extremity ischemia, physiologic studies (eg, ankle-brachial index) should be obtained. (See",
"      <a class=\"local\" href=\"#H94697943\">",
"       'Noninvasive vascular laboratory examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend observation with interval duplex ultrasound of asymptomatic iatrogenic arteriovenous fistula (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Due to the simplicity and minimal risk, ultrasound-guided compression (UGC) may be attempted in early acquired arteriovenous fistula, but should be abandoned if the patient experiences undue pain. An ultrasound probe is placed over the AVF to provide compression with a sufficient force to abolish flow through the fistula without unduly reducing distal perfusion. With USGC, up to one-third of patients may avoid the need for other forms of treatment. (See",
"      <a class=\"local\" href=\"#H94697830\">",
"       'Ultrasound-guided compression'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      For symptomatic AVF, we recommend surgical repair over no repair (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Endovascular repair with a covered stent or coil embolization are alternative treatments for patients who may not tolerate any degree of bleeding, have a hostile groin due to excessive scar tissue, or who have a prohibitive risk for anesthesia. (See",
"      <a class=\"local\" href=\"#H1229237957\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H94697837\">",
"       'Endovascular repair'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/1\">",
"      Kron J, Sutherland D, Rosch J, et al. Arteriovenous fistula: a rare complication of arterial puncture for cardiac catheterization. Am J Cardiol 1985; 55:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/2\">",
"      Glaser RL, McKellar D, Scher KS. Arteriovenous fistulas after cardiac catheterization. Arch Surg 1989; 124:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/3\">",
"      Schaub F, Theiss W, Heinz M, et al. New aspects in ultrasound-guided compression repair of postcatheterization femoral artery injuries. Circulation 1994; 90:1861.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/4\">",
"      Sako Y, Varco RL. Arteriovenous fistula: results of management of congenital and acquired forms, blood flow measurements, and observations on proximal arterial degeneration. Surgery 1970; 67:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/5\">",
"      Shumacker HB Jr. Aneurysm development and degenerative changes in dilated artery proximal to arteriovenous fistula. Surg Gynecol Obstet 1970; 130:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/6\">",
"      Kotelis D, Klemm K, von Tengg-Kobligk H, et al. Intermittent claudication secondary to a traumatic arteriovenous fistula. Vasa 2007; 36:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/7\">",
"      Kim D, Orron DE, Skillman JJ, et al. Role of superficial femoral artery puncture in the development of pseudoaneurysm and arteriovenous fistula complicating percutaneous transfemoral cardiac catheterization. Cathet Cardiovasc Diagn 1992; 25:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/8\">",
"      Oweida SW, Roubin GS, Smith RB 3rd, Salam AA. Postcatheterization vascular complications associated with percutaneous transluminal coronary angioplasty. J Vasc Surg 1990; 12:310.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/9\">",
"      Nasser TK, Mohler ER 3rd, Wilensky RL, Hathaway DR. Peripheral vascular complications following coronary interventional procedures. Clin Cardiol 1995; 18:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/10\">",
"      Lamar R, Berg R, Rama K. Femoral arteriovenous fistula as a complication of percutaneous transluminal coronary angioplasty. A report of five cases. Am Surg 1990; 56:702.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/11\">",
"      Altin RS, Flicker S, Naidech HJ. Pseudoaneurysm and arteriovenous fistula after femoral artery catheterization: association with low femoral punctures. AJR Am J Roentgenol 1989; 152:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/12\">",
"      Muller DW, Shamir KJ, Ellis SG, Topol EJ. Peripheral vascular complications after conventional and complex percutaneous coronary interventional procedures. Am J Cardiol 1992; 69:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/13\">",
"      Vaz C, Matos A, Oliveira J, et al. Iatrogenic arteriovenous fistula following endovenous laser therapy of the short saphenous vein. Ann Vasc Surg 2009; 23:412.e15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/14\">",
"      Pagnotta P, Briguori C, Presbitero P. Arteriovenous fistula complicating directional atherectomy of the popliteal artery. J Cardiovasc Med (Hagerstown) 2009; 10:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/15\">",
"      Noory E, Rastan A, Schwarzw&auml;lder U, et al. Retrograde transpopliteal recanalization of chronic superficial femoral artery occlusion after failed re-entry during antegrade subintimal angioplasty. J Endovasc Ther 2009; 16:619.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/16\">",
"      Kelm M, Perings SM, Jax T, et al. Incidence and clinical outcome of iatrogenic femoral arteriovenous fistulas: implications for risk stratification and treatment. J Am Coll Cardiol 2002; 40:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/17\">",
"      Perings SM, Kelm M, Jax T, Strauer BE. A prospective study on incidence and risk factors of arteriovenous fistulae following transfemoral cardiac catheterization. Int J Cardiol 2003; 88:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/18\">",
"      Meyerson SL, Feldman T, Desai TR, et al. Angiographic access site complications in the era of arterial closure devices. Vasc Endovascular Surg 2002; 36:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/19\">",
"      Omoigui NA, Califf RM, Pieper K, et al. Peripheral vascular complications in the Coronary Angioplasty Versus Excisional Atherectomy Trial (CAVEAT-I). J Am Coll Cardiol 1995; 26:922.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/20\">",
"      Lebreton G, Uzel AP, Celerien J, et al. Popliteal arteriovenous fistula due to a gunshot injury. Ann Vasc Surg 2010; 24:952.e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/21\">",
"      Paulson EK, Kliewer MA, Hertzberg BS, et al. Ultrasonographically guided manual compression of femoral artery injuries. J Ultrasound Med 1995; 14:653.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/22\">",
"      Toursarkissian B, Allen BT, Petrinec D, et al. Spontaneous closure of selected iatrogenic pseudoaneurysms and arteriovenous fistulae. J Vasc Surg 1997; 25:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/23\">",
"      Miller-Thomas MM, West OC, Cohen AM. Diagnosing traumatic arterial injury in the extremities with CT angiography: pearls and pitfalls. Radiographics 2005; 25 Suppl 1:S133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/24\">",
"      Waigand J, Uhlich F, Gross CM, et al. Percutaneous treatment of pseudoaneurysms and arteriovenous fistulas after invasive vascular procedures. Catheter Cardiovasc Interv 1999; 47:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/25\">",
"      Kirsch JD, Reading CC, Charboneau JW. Ultrasound-guided compression and repair of postangiographic femoral arteriovenous fistulas. Mayo Clin Proc 1993; 68:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/26\">",
"      Fellmeth BD, Roberts AC, Bookstein JJ, et al. Postangiographic femoral artery injuries: nonsurgical repair with US-guided compression. Radiology 1991; 178:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/27\">",
"      Ruebben A, Tettoni S, Muratore P, et al. Arteriovenous fistulas induced by femoral arterial catheterization: percutaneous treatment. Radiology 1998; 209:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/28\">",
"      Thalhammer C, Kirchherr AS, Uhlich F, et al. Postcatheterization pseudoaneurysms and arteriovenous fistulas: repair with percutaneous implantation of endovascular covered stents. Radiology 2000; 214:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/29\">",
"      Baltaciolu F, Cimit NC, Cil B, et al. Endovascular stent-graft applications in latrogenic vascular injuries. Cardiovasc Intervent Radiol 2003; 26:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/30\">",
"      Lemaire JM, Dondelinger RF. Percutaneous coil embolization of iatrogenic femoral arteriovenous fistula or pseudo-aneurysm. Eur J Radiol 1994; 18:96.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6231/abstract/31\">",
"      Brewster DC, Cambria RP, Moncure AC, et al. Aortocaval and iliac arteriovenous fistulas: recognition and treatment. J Vasc Surg 1991; 13:253.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8217 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-218.189.88.190-7920B88E07-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6231=[""].join("\n");
var outline_f6_5_6231=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H94697279\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94699883\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94700565\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94699890\">",
"      Percutaneous groin access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94697664\">",
"      Trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94697943\">",
"      Noninvasive vascular laboratory examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H94697718\">",
"      - Duplex ultrasonography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H94697951\">",
"      - ABI and lower extremity physiologic studies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H94699039\">",
"      - Arteriography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94697830\">",
"      Ultrasound-guided compression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1229237943\">",
"      Repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1229237957\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H94697837\">",
"      Endovascular repair",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94697906\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H94697279\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/8217\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8217|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/14/1249\" title=\"diagnostic image 1\">",
"      Doppler study lower extremity arteriovenous fistula",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/8217|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/51/24379\" title=\"table 1\">",
"      Etiology of arteriovenous fistulas",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/52/35656?source=related_link\">",
"      Clinical manifestations and diagnosis of patent ductus arteriosus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/42/42665?source=related_link\">",
"      Complications of diagnostic cardiac catheterization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/47/9978?source=related_link\">",
"      High-output heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/11/36024?source=related_link\">",
"      Placement of femoral venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/0/27656?source=related_link\">",
"      Pulmonary arteriovenous malformations: Epidemiology, etiology, pathology, and clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/57/12186?source=related_link\">",
"      Severe extremity injury in the adult patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/9/18584?source=related_link\">",
"      Vascular malformations of the central nervous system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_5_6232="Repair of common bile duct injuries";
var content_f6_5_6232=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Repair of common bile duct injuries",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/5/6232/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/5/6232/contributors\">",
"     Keith D Lillemoe, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/5/6232/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/5/6232/contributors\">",
"     Stanley W Ashley, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/5/6232/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/5/6232/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/5/6232/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 8, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common bile duct injuries represent a serious and challenging surgical complication. These complex injuries are most often a consequence of laparoscopic cholecystectomy (LC) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/1\">",
"     1",
"    </a>",
"    ]. Proper management requires a skilled and experienced hepatobiliary surgical team.",
"   </p>",
"   <p>",
"    This topic will focus on the surgical repair of common bile duct injuries. Details of LC techniques and endoscopic management of complications from LC are discussed elsewhere.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=see_link\">",
"       \"Laparoscopic cholecystectomy: Techniques\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"       \"Complications of laparoscopic cholecystectomy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12152?source=see_link\">",
"       \"Endoscopic management of complications from laparoscopic cholecystectomy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INCIDENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of cholecystectomies performed laparoscopically has increased steadily since the introduction of this technique in the early 1990s [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/2\">",
"     2",
"    </a>",
"    ]. Initially, the laparoscopic approach was associated with an almost tenfold increase in the incidence of bile duct injury as compared with open cholecystectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/1\">",
"     1",
"    </a>",
"    ]. Subsequently, large surveys have shown that the incidence of bile duct injury as a consequence of LC has decreased as surgeons have gained more experience with laparoscopic surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, the incidence of iatrogenic biliary injury remains higher than in the open cholecystectomy era [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     MECHANISM OF INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete transection of the common bile duct is the most frequent biliary injury, and the most challenging to manage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/4\">",
"     4",
"    </a>",
"    ]. This \"classic\" injury occurs when the common bile duct is mistaken for the cystic duct, resulting in clipping and division of the common duct, which is then resected with the gallbladder (",
"    <a class=\"graphic graphic_figure graphicRef63474 \" href=\"UTD.htm?21/48/22274\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/5\">",
"     5",
"    </a>",
"    ]. The injury is often compounded by excision of a segment of common duct and division of the common hepatic duct. Despite this sequence of events, biliary injury is recognized at the time of LC in a minority of cases.",
"   </p>",
"   <p>",
"    Contributing factors to bile duct injury include inflammation in the triangle of Calot, a short cystic duct, excessive cephalad retraction on the gallbladder fundus, and insufficient or excessive lateral retraction of the gallbladder infundibulum [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. Additionally, use of an end-viewing scope, excessive use of cautery, physician inexperience and aberrant biliary anatomy can play a role in these injuries. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of intraoperative cholangiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intraoperative cholangiography (IOC) can be used to define biliary anatomy. There is ongoing debate about whether routine IOC would help prevent bile duct injuries during LC [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/6\">",
"     6",
"    </a>",
"    ]. Some have maintained that routine IOC is technically challenging, adds cost and time to the procedure and is unnecessary for the majority of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/7\">",
"     7",
"    </a>",
"    ]. These surgeons selectively use preoperative endoscopic retrograde cholangiopancreatography (ERCP) and perform IOC based on abnormal liver function tests or a dilated common bile duct on preoperative ultrasound. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=see_link\">",
"     \"Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A survey of general surgeons in the United States demonstrated that only 27 percent use IOC routinely [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/8\">",
"     8",
"    </a>",
"    ]. However, others feel strongly that IOC should be performed routinely as part of all LC so that the operative team is familiar with the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/6,9-11\">",
"     6,9-11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A retrospective population based study showed that intraoperative cholangiography has a significant protective effect for bile duct injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/12\">",
"     12",
"    </a>",
"    ]. The rate of injury was 2.1 per 1000 when IOC was performed routinely during LC and 4.3 per 1000 when IOC was not done. The difference was more striking when the cases were complex rather than routine; the rate of injury was 2.2 per 1000 when IOC was performed and 16.9 per 1000 when IOC was not done. Several smaller studies have addressed this question prospectively:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a prospective study of 303 patients undergoing LC, 148 had IOC performed routinely and 155 had selective IOC [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/13\">",
"       13",
"      </a>",
"      ]. There was no significant difference in the mean operating time, retained common bile duct (CBD) stones or CBD injury.",
"     </li>",
"     <li>",
"      A prospective study of 1241 patients undergoing LC showed that routine IOC was feasible in 92 percent of cases and anatomic variations that influenced operative management were found in 13 percent of cases [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/14\">",
"       14",
"      </a>",
"      ]. There were no complications from the IOC but there were four bile duct injuries despite the use of IOC.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Taken together, this data suggests that IOC can be performed routinely without significant increases in operating room time or complications from the procedure. Routine performance of IOC helps to ensure that the surgical team is familiar with the procedure and that proper equipment is available. If atypical anatomy is encountered during LC, early conversion to an open laparotomy and prompt IOC are recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF BILIARY INJURIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Strasberg and Bismuth classifications of biliary injury are based upon the degree and level of injury (",
"    <a class=\"graphic graphic_figure graphicRef66356 \" href=\"UTD.htm?26/2/26662\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/4\">",
"     4",
"    </a>",
"    ]. This classification is widely used and is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     RECOGNITION OF BILE DUCT INJURY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In many cases, initial appropriate management of a bile duct injury recognized at the time of cholecystectomy can avoid the development of complications. About one-third of cases are recognized at the time of LC when sudden unexpected bile leakage is noted or a \"second\" cystic duct is encountered during the dissection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Intraoperative diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;If bile leakage is observed during LC, repair should be performed only if the surgeon is skilled in these procedures. If not, then transfer to a colleague or another institution is warranted. Laparotomy should not be performed for diagnosis or drainage alone, as this may compound the injury [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'When to postpone bile duct repair'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    If a bile leak is recognized by an experienced surgical team, then early conversion to an open laparotomy and prompt cholangiography should be performed. Cholangiography will define the proximal anatomy to ensure that all hepatic ducts are accounted for and included in the reconstruction (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71002 \" href=\"UTD.htm?0/25/402\">",
"     image 1",
"    </a>",
"    ). A study of 88 patients with major bile duct injuries showed that when a cholangiogram was performed and cholangiographic data were complete, the initial repair was successful in 16 of 19 patients (84 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/16\">",
"     16",
"    </a>",
"    ]. In contrast, repairs of bile duct injuries were unsuccessful in 27 of 28 patients (96 percent) when cholangiograms were not obtained before surgery. Additionally, the lack of complete cholangiographic information led to an inappropriate operation in some cases. Details of repair options are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     When to postpone bile duct repair",
"    </span>",
"    &nbsp;&mdash;&nbsp;In some situations, a surgeon may encounter a bile duct injury that he or she may feel uncomfortable in attempting to repair at the time of the original operation. This may be due to a very proximal injury, very small bile ducts, associated inflammation, or the technical limitations of the surgeon. In this situation, externally draining the biliary system to avoid bile peritonitis and transfer to a tertiary care biliary surgeon without an attempt at repair is the best option.",
"   </p>",
"   <p>",
"    If possible, a catheter, such as a pediatric feeding tube or cholangiocatheter, should be placed into the proximal transected duct. This catheter can be secured loosely with a suture or clip, but care should be taken not to damage the duct and sacrifice length that may be needed for eventual reconstruction. The catheter is valuable both in controlling the bile leak and allowing access for cholangiography to facilitate placement of percutaneous transhepatic biliary catheters in the postoperative period. In addition, a closed-section drain should be placed dependently in the gallbladder bed to further control the bile leak.",
"   </p>",
"   <p>",
"    The repair of a bile duct injury is a complicated procedure, and there is clear evidence that the best results are obtained at a center with experienced hepatobiliary surgeons and interventional radiologists [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. In one report, 64 biliary repairs performed by the primary surgeon or surgeons of comparable experiences were compared to 46 repairs performed by biliary surgeons at tertiary referral centers [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/16\">",
"     16",
"    </a>",
"    ]. A successful outcome was obtained in 94 percent of patients whose first repair was by a tertiary care biliary surgeon. In contrast, repair by the original laparoscopic surgeon was successful in only 17 percent of patients, and in no case was a second or third repair by the primary surgeon successful.",
"   </p>",
"   <p>",
"    The decision to transfer to a more experienced surgeon is considered good judgment and not \"abandonment.\" The patient and family should be carefully educated and advised about the reasoning for this decision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Delayed presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries that are not recognized at the time of surgery present in a delayed fashion as either a bile leak or obstruction. Bile leakage into the peritoneal cavity will lead to severe abdominal pain, distention, nausea and emesis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/18\">",
"     18",
"    </a>",
"    ]. If a bile leak is not controlled, this will result in a loculated collection, abscess formation, biliary ascites or bile peritonitis.",
"   </p>",
"   <p>",
"    Most patients with a major bile duct injury are not recognized at the original LC, but rather in the early postoperative period, either with symptoms of fever, abdominal pain, peritonitis or obstructive jaundice. The initial management of a patient who presents in a delayed fashion following a bile duct injury during LC depends on the nature of the injury and the mode and timing of the presentation. The diagnostic work-up and management of these patients is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Bile leak",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a patient presents early following cholecystectomy, the most common mode of presentation will be a bile leak. If exploration and an attempt at repair are performed when there is bile peritonitis due to an uncontrolled bile leak, the dissection in the right upper quadrant will be very difficult, and identification of the decompressed retracted biliary system may be impossible, especially in the hands of the inexperienced biliary surgeon. Biliary reconstruction under these circumstances is technically difficult and, if accomplished at all, will frequently lead to long-term failure in the form of recurrent leak or biliary stricture.",
"   </p>",
"   <p>",
"    Every attempt should be made to define the biliary anatomy using percutaneous cholangiography and to drain and control the bile leak with percutaneous biliary stents and percutaneous intraabdominal drains. Repair is then ideally performed six to eight weeks after control of the leak and after intraabdominal sepsis is resolved and intraabdominal inflammation is less. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/39/37491?source=see_link\">",
"     \"Percutaneous transhepatic cholangiography\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12152?source=see_link\">",
"     \"Endoscopic management of complications from laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Biliary obstruction",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients who present with jaundice",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cholangitis from biliary obstruction, defining the anatomy with percutaneous cholangiography and biliary drainage are important to control sepsis associated with cholangitis before planning elective repair. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/39/37491?source=see_link\">",
"     \"Percutaneous transhepatic cholangiography\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The clinical and radiologic evaluation of a bile leak or obstruction is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=see_link\">",
"     \"Complications of laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GOAL OF OPERATIVE MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The goal of operative management of a bile duct injury is the establishment of bile flow into the proximal gastrointestinal tract in a manner that prevents cholangitis, sludge, or stone formation, restricture or, at end stage, biliary cirrhosis. This goal is best accomplished with a tension-free anastomosis between healthy tissues.",
"   </p>",
"   <p>",
"    A number of surgical alternatives exist for the repair of bile duct injuries, including end-to-end repair, Roux-en-Y hepaticojejunostomy or choledochojejunostomy, and choledochoduodenostomy. The choice of repair depends on a number of factors, including the extent and location of the injury, the experience of the surgeon, and the timing of the repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     REPAIR OPTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of options are available for bile duct repair. The choice depends on the type and extent of injury:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Segmental or accessory duct injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;If a segmental or accessory duct less than 3 mm has been injured, and cholangiography demonstrates segmental or subsegmental drainage by the injured ductal system, simple ligation of the injured duct and placement of a drain is adequate [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/19\">",
"     19",
"    </a>",
"    ]. However, if the injured duct is 4 mm or larger, it is likely to drain multiple hepatic segments or the entire left or right lobe and therefore requires operative repair.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Choledochotomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A bile duct injury is sometimes recognized during the performance of an intraoperative cholangiogram (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef71002 \" href=\"UTD.htm?0/25/402\">",
"     image 1",
"    </a>",
"    ). Recognition usually occurs after the placement of a single clip across the bile duct, with the introduction of a cholangiocatheter via a small choledochotomy. In most situations, the clip should be removed and small choledochotomy closed with a single 4-0 or 5-0 absorbable suture. A t-tube (",
"    <a class=\"graphic graphic_figure graphicRef60196 \" href=\"UTD.htm?8/58/9122\">",
"     figure 3",
"    </a>",
"    ) may be necessary if the choledochotomy is large. In either case, a closed suction drain should be placed in the area to control any postoperative bile leak.",
"   </p>",
"   <p>",
"    The natural history of simple clip application across the bile duct is not defined, but it is unlikely that a late bile duct stricture would develop. If such a stricture does develop, the option of endoscopic management with balloon dilatation and stenting is available and is usually associated with an excellent outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12152?source=see_link\">",
"     \"Endoscopic management of complications from laparoscopic cholecystectomy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Transection of common bile duct",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common injury involves the complete transection of the common bile duct or the common hepatic duct. The aims of any repair should be to maintain ductal length and not sacrifice tissue, as well as to create a repair that will not result in postoperative bile leakage. To accomplish these goals, all repairs at the time of initial operation should include external drainage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Short injured segment or distal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;If an injured segment of bile duct is short (&lt;1 cm) and the two ends can be opposed without tension, an end-to-end anastomosis can be performed with placement of a T-tube through a separate choledochotomy either above or below the anastomosis (",
"    <a class=\"graphic graphic_figure graphicRef60196 \" href=\"UTD.htm?8/58/9122\">",
"     figure 3",
"    </a>",
"    ). This approach is seldom used, as it is associated with a high risk of stricture formation. Because the injured edges will need debridement before anastomosis, there are few cases where there will be sufficient healthy duct tissue to allow end-to-end anastomosis and accordingly the long-term success rate for this technique is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/16\">",
"     16",
"    </a>",
"    ]. In the majority of cases, a hepaticojejunostomy represents the best choice for repair.",
"   </p>",
"   <p>",
"    Advantages of the end-to-end anastomosis are that it is less complex and allows endoscopic transampullary cholangiography and stenting to treat any late stricture. If a Roux-limb is created and a stricture develops, percutaneous access will ultimately be necessary in almost all cases. Some groups have reported acceptable outcomes with end-to-end anastomosis. One retrospective study reported less early postoperative complications in 45 patients treated with end-to-end anastomosis than 49 patients who underwent hepaticojejunostomies [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/20\">",
"     20",
"    </a>",
"    ]. Long-term results of both surgical approaches were comparable. There were no significant differences in stricture formation, general health status or quality of life between the two groups.",
"   </p>",
"   <p>",
"    If this approach is chosen, generous mobilization of the duodenum out of the retroperitoneum (Kocher maneuver) can be used to help approximate the injured ends of the bile duct. A Kocher maneuver is the dissection of the lateral peritoneal attachments of the duodenum to allow inspection of the duodenum, pancreas, and other retroperitoneal structures [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of the choice of reconstruction, the surgeon should always consider getting an experienced colleague to help with both the intraoperative decision making and reconstruction, if available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Long injured segment or proximal injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;For proximal injuries or if the injured segment of bile duct is greater than 1 cm in length, an end-to-end bile duct anastomosis should be avoided because of the excessive tension that usually exists in these situations. In these circumstances, the distal bile duct should be oversewn, and the proximal bile duct should be debrided of injured tissue and anastomosed in an end-to-side fashioned to a Roux-en-Y jejunal limb. The use of a Roux-en-Y jejunal limb is preferable to an anastomosis to the duodenum because in the latter case an anastomotic leak can result in a duodenal fistula. A trans-anastomotic stent can be placed retrograde to the transected duct exiting the hepatic parenchyma to allow postoperative external drainage. In addition, a closed suction drain should be placed in the area of the anastomosis to control any postoperative bile leak (",
"    <a class=\"graphic graphic_figure graphicRef55673 \" href=\"UTD.htm?27/39/28277\">",
"     figure 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The details of reconstruction vary depending upon the particular anatomic features of the injury or stricture:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Type E1 (Bismuth I)",
"    </span>",
"    &nbsp;&mdash;&nbsp;For injuries with over 2 cm of healthy common hepatic duct preserved, a simple end-to-side biliary enteric anastomosis to a Roux-limb will suffice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Type E2 and E3 (Bismuth II and III)",
"    </span>",
"    &nbsp;&mdash;&nbsp;For injuries in which less than 2 cm of healthy hepatic duct is preserved (Bismuth II), or that involve the bifurcation of the hepatic ducts, but in which the right and left ducts communicate (Bismuth III), the hilar plate of the liver may need to be lowered and the dochotomy extended along a short length of the right or left hepatic duct to allow a common biliary enteric anastomosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Type E4 (Bismuth IV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Injuries that completely separate the right and left systems (Bismuth IV) require separate right and left biliary enteric anastomoses. In rare cases, suitable duct length outside the hepatic parenchyma cannot be obtained, and these cases necessitate isolation of the intrahepatic biliary system. Intraoperative ultrasound may be necessary in these situations.",
"   </p>",
"   <p>",
"    The segment II duct can be located and isolated as it courses superficially in the inferior posterior surface of this segment to the liver. The parenchyma is excised over the duct, and the duct is opened along its length for 2 cm. A side-to-side biliary enteric anastomosis to a Roux-limb is then created.",
"   </p>",
"   <p>",
"    Similarly, the segment III duct can be isolated on the medial anterior surface of segment III, just lateral to the insertion of the falciform ligament. This duct is located deep in the liver parenchyma, and a wedge of liver parenchyma must be removed to complete the exposure of the duct.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Type E5 (Bismuth V)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common procedure for biliary reconstruction following a Type E5 injury is Roux-en-Y hepaticojejunostomy with trans-anastomotic stents (",
"    <a class=\"graphic graphic_figure graphicRef67421 \" href=\"UTD.htm?29/21/30036\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Operative technique",
"    </span>",
"    &nbsp;&mdash;&nbsp;If biliary stents are in place prior to surgery, these should be advanced by the interventional radiologist across the transected segment of duct into the subhepatic space. If the duct is \"completely clipped off,\" the catheters should be advanced right up to the transected end. This is important, as the catheters will help the surgeon identify the transected duct, which is usually retracted to the liver and surrounded by inflammation and adhesions.",
"   </p>",
"   <p>",
"    The bile duct proximal to the injury is carefully dissected circumferentially in a cephalad direction for a distance not to exceed 5 mm. This process is facilitated by having a biliary catheter extending through the end of the transected duct. The catheter can be identified early and followed back to the transected duct, which facilitates mobilization prior to reconstruction. Excessive proximal dissection of the transected duct should be avoided to prevent vascular compromise of the duct. A radiologic guide wire is then placed in the catheter(s).",
"   </p>",
"   <p>",
"    A series of Coud&eacute; catheters may then be passed over the guide wire, to dilate the system, and then the appropriately sized, soft silastic stents are placed over the guide wires. The silastic stents are 12-22 French in size and have multiple side holes along 40 percent of their length. The side holes are left to reside within the intrahepatic biliary tree and the portion of the Roux-en-Y jejunal limb used for the biliary anastomosis. The end of the stent without the side holes exits through the liver parenchyma and is brought out through a stab wound in the upper abdominal wall. The biliary stents help decrease the possibility of stricture at the anastomosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/22\">",
"     22",
"    </a>",
"    ]. Silastic is soft and non-reactive, which minimizes the possibility of tissue damage and maximizes patient comfort. The multiple side holes help facilitate flushing and prevent obstruction of the biliary flow.",
"   </p>",
"   <p>",
"    After the stents have been placed, a Roux-en-Y limb is prepared and the anastomosis completed as an end-to-side hepaticojejunostomy. The anastomosis is usually done with interrupted 4-0 or 5-0 absorbable sutures.",
"   </p>",
"   <p>",
"    Closed suction drains are placed behind the anastomosis. Postoperatively, the silastic stents are left to gravity drainage for three to four days. A postoperative cholangiogram is then performed, and if that study is satisfactory, the stents are internalized (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef75876 \" href=\"UTD.htm?23/32/24064\">",
"     image 2",
"    </a>",
"    ). The length of time that the stents are left in place after surgery is variable and determined by the nature of the injury, the patient's clinical course, and follow-up cholangiography.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The perioperative outcomes of surgical repair for biliary injuries following laparoscopic surgery have been reported in a series of 200 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/23\">",
"     23",
"    </a>",
"    ]. The postoperative mortality was 1.7 percent and the incidence of postoperative complications was 43 percent. The most common complications were wound infections (8 percent), cholangitis (6 percent), and intraabdominal abscess (3 percent). Early postoperative cholangiography revealed an anastomotic leak in 5 percent and extravasation of the liver dome-stent site in 10 percent of patients. None of the patients required reoperation. Postoperative radiologic intervention, including percutaneous abscess drainage, was required in nine patients (5 percent), and new stent placement was required in four patients (2 percent). Similar results have been reported in other series [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A study of long-term outcomes in 142 patients following surgery for bile duct injuries showed that a successful outcome without the need for long-term biliary stents was ultimately achieved in 98 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/17\">",
"     17",
"    </a>",
"    ]. Patients who failed initial surgical management underwent either surgical revision (one case) or balloon dilatation. Only three patients continued to require long-term biliary stents to prevent symptoms, biliary obstruction,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cholangitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Quality of life",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have examined quality of life (QOL) of patients following surgical repair of bile duct injuries, and most demonstrate return of the individual to baseline functional health. One study compared QOL in patients who underwent successful surgical reconstruction of bile duct injury to age-matched individuals who had undergone recent uncomplicated LC and to age-matched healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6232/abstract/25\">",
"     25",
"    </a>",
"    ]. The patients that had a successful bile duct reconstruction were not statistically different from the controls in the physical and social domains, but did score lower in the psychological domain of the assessment. The pursuit of a lawsuit related to the injury appeared to be a significant factor in influencing the quality of life in all domains. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4120?source=see_link\">",
"     \"Evaluation of health-related quality of life\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Common bile duct injuries represent a serious and challenging surgical complication. These complex injuries are most often a consequence of laparoscopic cholecystectomy. Proper management requires that the surgical team has appropriate skill and experience with complex hepatobiliary surgery. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Injury to the common bile duct occurs most commonly when it is mistaken for the cystic duct. Intraoperative cholangiography delineates biliary anatomy, and thus, may decrease the risk of iatrogenic common bile duct injury. Cholangiography is performed routinely by some surgeons to reinforce familiarity with the procedure and should be performed with a low threshold in any patient for whom anatomic abnormalities are suspected. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Mechanism of injury'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The Strasberg and Bismuth classifications of biliary injury are based upon the degree and level of injury (",
"      <a class=\"graphic graphic_figure graphicRef63474 \" href=\"UTD.htm?21/48/22274\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      About one-third of bile duct injuries are recognized at the time of laparoscopic cholecystectomy. If bile leakage is observed after the completion of the cholecystectomy, the appropriately-trained surgeon proceeds with conversion to an open procedure, intraoperative cholangiography, and repair. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Intraoperative diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Immediate repair is best not attempted in patients with a very proximal bile duct injury, very small bile ducts, or associated inflammation. Drainage should be established to control the bile leak and prevent bile peritonitis. The patient should be transferred to an appropriate facility, if the treating surgeon has limited experience with complex hepatobiliary surgery. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'When to postpone bile duct repair'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most patients with a major bile duct injury are not recognized intraoperatively during laparoscopic cholecystectomy, but present in a delayed manner with postoperative fever, abdominal pain, peritonitis indicative of a bile leak, or obstructive jaundice. For patients who present with a postoperative bile leak, percutaneous cholangiography is performed to define the biliary anatomy, and the bile leak controlled using percutaneous biliary stents or intraabdominal drains. Repair is performed six to eight weeks after control of the leak once intraabdominal sepsis is resolved. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Delayed presentation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H10\">",
"       'Bile leak'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who present with biliary obstruction, cholangiography and biliary drainage are indicated to control sepsis associated with cholangitis prior to repair. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Biliary obstruction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The goal of operative management of a bile duct injury is to re-establish flow of bile into the proximal gastrointestinal tract in a manner that prevents sludge, stone formation, stricture, cholangitis, and biliary cirrhosis. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Goal of operative management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest end-to-side over end-to-end anastomosis for hepaticojejunostomy as the best option for the repair for most common bile duct injuries (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Repair options'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of patients undergoing surgery for bile duct injuries achieve a successful outcome without the need for long-term biliary stents. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/1\">",
"      McPartland KJ, Pomposelli JJ. Iatrogenic biliary injuries: classification, identification, and management. Surg Clin North Am 2008; 88:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/2\">",
"      Dolan JP, Diggs BS, Sheppard BC, Hunter JG. Ten-year trend in the national volume of bile duct injuries requiring operative repair. Surg Endosc 2005; 19:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/3\">",
"      Hall JG, Pappas TN. Current management of biliary strictures. J Gastrointest Surg 2004; 8:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/4\">",
"      Strasberg SM, Hertl M, Soper NJ. An analysis of the problem of biliary injury during laparoscopic cholecystectomy. J Am Coll Surg 1995; 180:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/5\">",
"      Branum G, Schmitt C, Baillie J, et al. Management of major biliary complications after laparoscopic cholecystectomy. Ann Surg 1993; 217:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/6\">",
"      Massarweh NN, Flum DR. Role of intraoperative cholangiography in avoiding bile duct injury. J Am Coll Surg 2007; 204:656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/7\">",
"      Ladocsi LT, Benitez LD, Filippone DR, Nance FC. Intraoperative cholangiography in laparoscopic cholecystectomy: a review of 734 consecutive cases. Am Surg 1997; 63:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/8\">",
"      Massarweh NN, Devlin A, Elrod JA, et al. Surgeon knowledge, behavior, and opinions regarding intraoperative cholangiography. J Am Coll Surg 2008; 207:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/9\">",
"      Ferguson CM, Rattner DW, Warshaw AL. Bile duct injury in laparoscopic cholecystectomy. Surg Laparosc Endosc 1992; 2:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/10\">",
"      Woods MS, Traverso LW, Kozarek RA, et al. Characteristics of biliary tract complications during laparoscopic cholecystectomy: a multi-institutional study. Am J Surg 1994; 167:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/11\">",
"      Woods MS, Traverso LW, Kozarek RA, et al. Biliary tract complications of laparoscopic cholecystectomy are detected more frequently with routine intraoperative cholangiography. Surg Endosc 1995; 9:1076.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/12\">",
"      Fletcher DR, Hobbs MS, Tan P, et al. Complications of cholecystectomy: risks of the laparoscopic approach and protective effects of operative cholangiography: a population-based study. Ann Surg 1999; 229:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/13\">",
"      Amott D, Webb A, Tulloh B. Prospective comparison of routine and selective operative cholangiography. ANZ J Surg 2005; 75:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/14\">",
"      Ludwig K, Bernhardt J, Lorenz D. Value and consequences of routine intraoperative cholangiography during cholecystectomy. Surg Laparosc Endosc Percutan Tech 2002; 12:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/15\">",
"      Strasberg SM. Biliary injury in laparoscopic surgery: part 2. Changing the culture of cholecystectomy. J Am Coll Surg 2005; 201:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/16\">",
"      Stewart L, Way LW. Bile duct injuries during laparoscopic cholecystectomy. Factors that influence the results of treatment. Arch Surg 1995; 130:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/17\">",
"      Lillemoe KD, Melton GB, Cameron JL, et al. Postoperative bile duct strictures: management and outcome in the 1990s. Ann Surg 2000; 232:430.",
"     </a>",
"    </li>",
"    <li>",
"     Baker, MS, Lillemoe, KD. Benign biliary strictures. In: Current surgical therapy, 9th ed, Cameron, JL (Ed), Mosby, St. Louis 2008. p 420.",
"    </li>",
"    <li>",
"     Oddsdottir, M, Hunter, JG. Gallbladder and the extrahepatic biliary system. In: Schwartz's principles of surgery, 8th ed, Brunicardi, FC, et al (Eds), McGraw-Hill, New York 2005. p 1212.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/20\">",
"      Jaboska B, Lampe P, Olakowski M, et al. Hepaticojejunostomy vs. end-to-end biliary reconstructions in the treatment of iatrogenic bile duct injuries. J Gastrointest Surg 2009; 13:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/21\">",
"      Surgical Maneuvers. Arch Surg 1999; 134:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/22\">",
"      Kaufman SL, Cameron JL, Adams PE, et al. The management of surgically placed silastic transhepatic biliary stents. AJR Am J Roentgenol 1984; 142:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/23\">",
"      Sicklick JK, Camp MS, Lillemoe KD, et al. Surgical management of bile duct injuries sustained during laparoscopic cholecystectomy: perioperative results in 200 patients. Ann Surg 2005; 241:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/24\">",
"      Walsh RM, Henderson JM, Vogt DP, Brown N. Long-term outcome of biliary reconstruction for bile duct injuries from laparoscopic cholecystectomies. Surgery 2007; 142:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6232/abstract/25\">",
"      Melton GB, Lillemoe KD, Cameron JL, et al. Major bile duct injuries associated with laparoscopic cholecystectomy: effect of surgical repair on quality of life. Ann Surg 2002; 235:888.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3682 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-E570A510C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6232=[""].join("\n");
var outline_f6_5_6232=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INCIDENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      MECHANISM OF INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of intraoperative cholangiography",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLASSIFICATION OF BILIARY INJURIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      RECOGNITION OF BILE DUCT INJURY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Intraoperative diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      When to postpone bile duct repair",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Delayed presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Bile leak",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Biliary obstruction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GOAL OF OPERATIVE MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      REPAIR OPTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Segmental or accessory duct injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Choledochotomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Transection of common bile duct",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Short injured segment or distal injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Long injured segment or proximal injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Type E1 (Bismuth I)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Type E2 and E3 (Bismuth II and III)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Type E4 (Bismuth IV)",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Type E5 (Bismuth V)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Operative technique",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/3682\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/3682|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?0/25/402\" title=\"diagnostic image 1\">",
"      Intraoperative cholangiogram of possible bile duct injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?23/32/24064\" title=\"diagnostic image 2\">",
"      Cholangiogram of hepaticojejunostomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/3682|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/48/22274\" title=\"figure 1\">",
"      Bile duct injury during laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/2/26662\" title=\"figure 2\">",
"      Classification of iatrogenic bile duct injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/58/9122\" title=\"figure 3\">",
"      Repair of common bile duct injury over a T tube",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?27/39/28277\" title=\"figure 4\">",
"      Transhepatic biliary drain placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?29/21/30036\" title=\"figure 5\">",
"      Biliary reconstruction with Roux-en-Y hepaticojejunostomy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18792?source=related_link\">",
"      Complications of laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12152?source=related_link\">",
"      Endoscopic management of complications from laparoscopic cholecystectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/1/4120?source=related_link\">",
"      Evaluation of health-related quality of life",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11338?source=related_link\">",
"      Laparoscopic cholecystectomy: Techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/49/39705?source=related_link\">",
"      Overview of indications for and complications of ERCP and endoscopic biliary sphincterotomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/39/37491?source=related_link\">",
"      Percutaneous transhepatic cholangiography",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_5_6233="Necrotizing fasciitis";
var content_f6_5_6233=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F62231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F62231&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Necrotizing fasciitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 655px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Necrotizing fasciitis is a rapidly progressing, life threatening soft tissue infection. Surgical treatment consists of wide debridement of skin, subcutaneous tissue, fascia, and any necrotic muscle.",
"    <br>",
"     (A) Necrotizing fasciitis in an immune-compromised elderly patient. Note that the proximal extent of the erythema has been marked with an indelible marker.",
"     <br>",
"      (B) Necrotizing fasciitis of the upper extremity. Left: Pre-operative appearance. Center: Intra-operative appearance. Arrow shows the bubbly purulent material. Right: Result after multiple debridements.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6233=[""].join("\n");
var outline_f6_5_6233=null;
var title_f6_5_6234="Human ehrlichiosis and anaplasmosis";
var content_f6_5_6234=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Human ehrlichiosis and anaplasmosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/5/6234/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/5/6234/contributors\">",
"     Daniel J Sexton, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/5/6234/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/5/6234/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/5/6234/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?6/5/6234/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?6/5/6234/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?6/5/6234/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 14, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first case of human ehrlichiosis was described in 1986 when a patient became ill with fever, hypotension, confusion, acute renal failure, coagulopathy, and gastrointestinal hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/1\">",
"     1",
"    </a>",
"    ]. The etiologic agent was identified as Ehrlichia chaffeensis, the agent of human monocytic ehrlichiosis (HME). In 1994, Anaplasma phagocytophilum was identified as the agent of human granulocytic anaplasmosis (HGA) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/2\">",
"     2",
"    </a>",
"    ]. HGA was previously called human granulocytic ehrlichiosis (HGE). Both of these tick-borne illnesses are recognized as separate disease entities, even though their clinical and laboratory manifestations are similar.",
"   </p>",
"   <p>",
"    The epidemiology, clinical manifestations, diagnosis, and treatment of human ehrlichiosis will be reviewed here. The microbiology of ehrlichial organisms and the mechanisms by which they cause disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23525?source=see_link\">",
"     \"Biology of ehrlichiae\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MICROBIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ehrlichiae are obligate intracellular bacteria that grow within membrane bound vacuoles in human and animal leukocytes (",
"    <a class=\"graphic graphic_picture graphicRef61249 graphicRef50113 \" href=\"UTD.htm?1/38/1642\">",
"     picture 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef71396 \" href=\"UTD.htm?17/31/17906\">",
"     picture 2",
"    </a>",
"    ). The taxonomy, phylogeny, and host specificity of these bacteria are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23525?source=see_link\">",
"     \"Biology of ehrlichiae\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The two most important species to infect humans include Ehrlichia chaffeensis, the causative agent of human monocytic ehrlichiosis (HME), and Anaplasma phagocytophilum, the agent of human granulocytic anaplasmosis (HGA). Less commonly, ehrlichiosis is caused by E. ewingii, which was discovered in 1999 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/3\">",
"     3",
"    </a>",
"    ]. In 2011, a third species of Ehrlichia was identified in four patients from Wisconsin and Minnesota who had fever, malaise, headache, and lymphopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/4\">",
"     4",
"    </a>",
"    ]. Molecular methods, culture techniques, and serologic testing have demonstrated that this new species is closely related to E. muris, which is found in Eastern Europe and Asia. These epidemiologic findings are important since ehrlichiosis has not been previously described in Wisconsin or Minnesota. &nbsp;",
"   </p>",
"   <p>",
"    Another species less commonly seen is Neorickettsia sennetsu, which causes a mild mononucleosis-like illness. Neorickettsial illness has not been reported outside the Far East and Southeast Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The epidemiologic features of human monocytic ehrlichiosis (HME) and human granulocytic anaplasmosis (HGA) are similar (",
"    <a class=\"graphic graphic_table graphicRef64475 \" href=\"UTD.htm?18/42/19115\">",
"     table 1",
"    </a>",
"    ). In 2010, US cases attributed to E. chaffeensis, the causative agent of HME, declined almost 22 percent (944 to 740), whereas those cases attributed to A. phagocytophilum, the causative agent of HGA, increased by 52 percent (1161 to 1761) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/6\">",
"     6",
"    </a>",
"    ]. Most cases occur in the spring and summer months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Human monocytic ehrlichiosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;HME is endemic in the southeastern, south central, and mid-Atlantic regions of the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/6\">",
"     6",
"    </a>",
"    ]. A few cases of HME have been recognized in New England and the Pacific Northwest, and isolated cases have been reported in Europe, Africa, and Mexico [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/7\">",
"     7",
"    </a>",
"    ]. Serological studies have suggested that E. chaffeensis also occurs in Mexico, Venezuela, Brazil, and Chile. Serological and molecular testing of vertebrates and humans have detected E. chaffeensis or a closely related ehrlichial agent in Venezuela [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/8\">",
"     8",
"    </a>",
"    ], China, Korea, Croatia, Poland, Greece, Italy and several countries in central Africa [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The average reported annual incidence of HME in the United States was 0.7 cases per million population in 2002, with wide variations in incidence by state [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/10\">",
"     10",
"    </a>",
"    ]. The total number of cases of HME reported annually to the CDC quadrupled from 2000 to 2008 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/11\">",
"     11",
"    </a>",
"    ]. However, these numbers likely underestimate the actual incidence of the disease as many cases are not confirmed by laboratory testing and current surveillance systems rely on voluntary reporting by clinicians. Depending on geographical location and exposure history, incidence rates as high as 660 per 100,000 have been reported in outbreak situations, while serologic surveys also show evidence of asymptomatic infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Tick bites, exposure to wildlife, and golfing have been associated with an increased risk of infection. In some locations, HME may be more common than Rocky Mountain spotted fever (RMSF) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Rocky Mountain spotted fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Human granulocytic anaplasmosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The HGA agent, E. phagocytophila, and E. equi are now recognized as the same organism that has been renamed Anaplasma phagocytophilum.",
"   </p>",
"   <p>",
"    HGA is more frequently reported than HME in the United States, with an average reported annual incidence of 1.6 cases per million population during 2001 to 2002 (",
"    <a class=\"graphic graphic_figure graphicRef72124 \" href=\"UTD.htm?23/48/24323\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/10\">",
"     10",
"    </a>",
"    ]. The number of cases of HGA reported to the CDC increased more than threefold from 2000 to 2008 (from 351 to 1053 cases) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/11\">",
"     11",
"    </a>",
"    ]. These estimates are likely to be inaccurate, because reporting is a passive process and because a significant number of cases diagnosed on clinical grounds are not confirmed serologically. In addition, serologic studies of persons with a history of tick bites suggest that many infections are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/15\">",
"     15",
"    </a>",
"    ]. Regional estimates of HGA vary significantly by locale; states with the highest incidence are Rhode Island (36.5 cases per million), Minnesota (3.9 to 12.3 cases per million), Connecticut (8.1 to 15.9 cases per million), Wisconsin (8.8 to 9.5 cases per million), New York (2.3 to 2.7 cases per million), and Maryland (1.6 cases per million).",
"   </p>",
"   <p>",
"    Infection with HGA is also recognized in Europe with similar risk factors of tick bite exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. The majority of human cases in Europe have been reported from Central Europe (eg, Slovenia) and Scandinavia (eg, Sweden) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/19\">",
"     19",
"    </a>",
"    ]. Although numerous studies done in various European countries have shown that A. phagocytophilum is commonly present in rodents, small mammals, and ticks, relatively few human cases of HGA have been recognized and the course of disease when infection does occur appears to be less severe than that seen in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/20\">",
"     20",
"    </a>",
"    ]. It is currently unknown if these findings are due to the presence of less pathogenic or nonpathogenic variants of A. phagocytophilum in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     E. ewingii infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1999, E. ewingii, the agent of canine granulocytic ehrlichiosis, was also found to cause disease in humans. Several of these cases occurred in Missouri, an area endemic for E. chaffeensis, and the clinical features of illness in these patients were initially confused with those of HME [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/3\">",
"     3",
"    </a>",
"    ]. Subsequently however, polymerase chain reaction (PCR) distinguished the organism in these cases from E. chaffeensis; morulae were observed in granulocytes in two of the patients, and one patient's dogs displayed a serologic reaction similar to the patient.",
"   </p>",
"   <p>",
"    Human ewingii infection has thus far only been reported in patients from Missouri, Oklahoma, and Tennessee, but because the vector for this disease (the Lone Star tick) is distributed over a wide area, it is likely that the geographic range of E. ewingii infection is much wider. Most human E. ewingii infections have been recognized in immunocompromised patients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TICK VECTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The principal vector of E. chaffeensis (agent of HME) is the Lone Star tick (Amblyomma americanum) (",
"    <a class=\"graphic graphic_picture graphicRef71086 \" href=\"UTD.htm?23/1/23582\">",
"     picture 3",
"    </a>",
"    ). Other ticks such as A. maculatum, D. variabilis and I. pacificus have occasionally been found to contain E. chaffeensis DNA, but their role in transmission is either minor or unlikely. Surveys of A. americanum ticks have shown rates of infection ranging from 0 to 27 percent; these wide ranges have been noted not only from different geographic locations, but also from the same location sampled at different times [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/9\">",
"     9",
"    </a>",
"    ]. The tick vectors of E. chaffeensis, found in South America, Asia and Africa, have not been firmly identified [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/9\">",
"     9",
"    </a>",
"    ]. Epidemiologic studies suggest that the tick vector for a novel ehrlichial species, identified in Wisconsin and Minnesota in 2011, is Ixodes scapularis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A. phagocytophilum (agent of HGA) may be transmitted by Ixodes scapularis (",
"    <a class=\"graphic graphic_picture graphicRef73802 \" href=\"UTD.htm?14/13/14558\">",
"     picture 4",
"    </a>",
"    ), the tick that is also the vector of Lyme disease and babesiosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/22\">",
"     22",
"    </a>",
"    ]. In studies of I. scapularis ticks from different locales, 2.2 to 26 percent of ticks were coinfected with Borrelia burgdorferi (agent of Lyme disease) and A. phagocytophilum [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. In fact, coinfection with HGA and Lyme disease occurs in approximately 3 to 15 percent of patients living in Connecticut and Wisconsin [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/24\">",
"     24",
"    </a>",
"    ]. I. pacificus (",
"    <a class=\"graphic graphic_picture graphicRef60501 \" href=\"UTD.htm?26/25/27038\">",
"     picture 5",
"    </a>",
"    ), the western black-legged tick, is the primary vector of HGA in the western United States and I. ricinus is the presumed vector in Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/15\">",
"     15",
"    </a>",
"    ]. The distribution of vector tick species is partially overlapping in the United States (",
"    <a class=\"graphic graphic_figure graphicRef56962 \" href=\"UTD.htm?26/28/27078\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     ANIMAL RESERVOIRS",
"    </span>",
"    &nbsp;&mdash;&nbsp;White tail deer are the principal animal reservoir for HME, and deer and the white-footed mouse are the principal animal hosts for HGA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/25\">",
"     25",
"    </a>",
"    ]. Although E. chaffeensis infection has been noted in coyotes and goats, their role in the epidemiology of HME remains to be determined [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/9,26-28\">",
"     9,26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Other modes of transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although ehrlichiosis is primarily a tick-borne disease, transmission by other means has been suggested, such as maternal-child transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/29\">",
"     29",
"    </a>",
"    ], blood transfusion [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/30\">",
"     30",
"    </a>",
"    ], and through direct contact with slaughtered deer [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nosocomial transmission of A. phagocytophilum was strongly suggested by a cluster of nine cases in China [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/32\">",
"     32",
"    </a>",
"    ]. Five family members and four health care providers became ill within 9 to 17 days after exposure to an index patient whose fatal illness was characterized by fever, hemorrhage, and multi-system failure. Contact investigation found that all nine secondary cases had exposure to blood; none had a history of a tick bite.",
"   </p>",
"   <p>",
"    This case series strongly suggests the possibility of human-to-human transmission of A. phagocytophilum and this is the first report of this disease in China. Limitations of this report include lack of any diagnostic testing for Anaplasma in the index case [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/33\">",
"     33",
"    </a>",
"    ]; secondary cases had A. phagocytophilum DNA in their bloodstream by PCR testing and subsequent seroconversion; diagnostic technology for confirmatory cultures was not available.",
"   </p>",
"   <p>",
"    As noted for ehrlichiosis, transmission of anaplasma through blood transfusion has also been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Adults",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most published data relate to infection in adults. Both HME and HGA typically present as an acute illness; however, there is a wide spectrum of disease, from subclinical and self-limited to subacute or chronic infection. Older patients and those with comorbid illnesses or immunosuppressive conditions such as HIV appear to have more severe infections [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most ehrlichial diseases have an incubation period of one to two weeks, but a shorter period may be seen. In a study of 18 adults with HGA, for example, symptoms appeared an average of 5.5 days after a tick bite was noted [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/35\">",
"     35",
"    </a>",
"    ]. Both HGA and HME produce variable symptoms, the severity of which can range from mild to severe.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients are febrile, but clinically mild or inapparent infection probably occurs.",
"     </li>",
"     <li>",
"      Nonspecific symptoms such as malaise, myalgia, headache, and chills occur in over two-thirds of cases, while nausea, vomiting, arthralgias, and cough occur in 25 to 50 percent.",
"     </li>",
"     <li>",
"      Rash, which can be macular, maculopapular, or petechial, occurs in a minority of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/36\">",
"       36",
"      </a>",
"      ]. In one review of 211 cases of HME, for example, rash was noted in 36 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/37\">",
"       37",
"      </a>",
"      ]. In contrast, rash is a rare finding in HGA infection, occurring in only 1 of 41 patients in one report [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/38\">",
"       38",
"      </a>",
"      ]. Some experts caution that when rash is present in a patient with HGA, the possibility of co-infection with B. burgdorferi or infection with another agent such as R. rickettsii or the meningococcus should be suspected [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/15\">",
"       15",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Neurologic symptoms, including mental status changes, stiff neck, and clonus, are less common. In a retrospective review, CSF samples were obtained for neurologic signs or symptoms in 15 of 57 patients (26 percent) with a confirmed diagnosis of Ehrlichia infection [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/39\">",
"       39",
"      </a>",
"      ]. Eight of the samples were abnormal; the most common abnormalities were lymphocytic pleocytosis and elevated protein levels. In a case report of ehrlichial meningitis, characteristic inclusions within mononuclear cells were seen in the CSF, compatible with Ehrlichia morulae [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/40\">",
"       40",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Some patients present subacutely with unexplained fever, and fever can persist for up to two months in the absence of therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/36,41\">",
"       36,41",
"      </a>",
"      ]. In one study, for example, 6 of 41 cases of HME recognized at a medical center in Missouri during a four-year span had protracted fever ranging in duration from 17 to 51 days [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/41\">",
"       41",
"      </a>",
"      ]. Another report described an untreated patient with HGA in whom A. phagocytophilum DNA was detected 21 days after the onset of symptoms despite the presence of high antibody titers [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data in children with ehrlichiosis have largely consisted of case reports and small series. A report from the Tick-Borne Infections in Children Study Group evaluated 32 children with HME in the \"tick belt\" in the southeastern United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/43\">",
"     43",
"    </a>",
"    ]. The major disease manifestations were fever in all patients, headache, myalgia, and rash (66 to 69 percent), and",
"    <span class=\"nowrap\">",
"     nausea/vomiting,",
"    </span>",
"    altered mental status, and lymphadenopathy (47 to 56 percent). The triad of fever, headache, and rash was present in 48 percent. These findings are similar to those in adults.",
"   </p>",
"   <p>",
"    A minority of the children had severe disease. Seven (22 percent) were admitted to the intensive care unit, four of whom required ventilatory and hemodynamic support.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Special hosts",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe disease has been reported in patients with factors leading to impaired immunity, such as advanced age, immunosuppressive agents, chronic illnesses, and malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/15,44,45\">",
"     15,44,45",
"    </a>",
"    ]. Data are limited on the effect of pregnancy, which can be associated with an increase in severity of some infections. In a case series of six pregnant women with HGA, all had mild disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/46\">",
"     46",
"    </a>",
"    ]. However, one report described a pregnant woman with HGA who spontaneously aborted her child while being treated for HGA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of laboratory abnormalities occur in ehrlichial infection. The most common, occurring in 50 to 90 percent of patients, are leukopenia (often accompanied by a left shift), thrombocytopenia, and elevated plasma levels of aminotransferases (transaminases), lactate dehydrogenase, and alkaline phosphatase [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/38,43,48\">",
"     38,43,48",
"    </a>",
"    ]. Anemia and an elevated plasma creatinine concentration also may be seen.",
"   </p>",
"   <p>",
"    Leukopenia in patients with HGA can be caused by lymphopenia or neutropenia. Lymphopenia tends to occur in the early stages of infection, followed by lymphocytosis with atypical lymphocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/35\">",
"     35",
"    </a>",
"    ]. In contrast, the initial neutrophil count in patients with HGA is inversely related to the duration of symptoms before treatment is begun. In one study, for example, neutropenia was seen in three of four patients who had HGA for more than four days versus only one in nine patients with a shorter duration of illness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thrombocytopenia was observed more often than leukopenia in a retrospective study of 144 patients with HGA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/49\">",
"     49",
"    </a>",
"    ]. This study also included matched controls with other acute febrile illnesses, and the risk of having ehrlichiosis in this group of patients varied inversely with granulocyte and platelet counts. The number of band neutrophils was also increased in most patients with HGA from the time of onset through the eighth day of illness. The authors emphasized that automated differential counting of leukocytes does not separate band neutrophils from segmented neutrophils or detect morulae, and they stressed the important point that a manual differential count should be ordered if ehrlichiosis is suspected.",
"   </p>",
"   <p>",
"    Changes in the cerebrospinal fluid are common in patients in whom a lumbar puncture is performed because of neurologic symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/39\">",
"     39",
"    </a>",
"    ]. In one report, for example, lymphocytic pleocytosis and elevated CSF protein levels were found in 21 of 38 patients with E. chaffeensis infection. In contrast, patients with HGA who have neurological symptoms typically have relatively normal CSF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications of ehrlichial infection include seizures, coma, and renal and respiratory failure. Heart failure can occur in previously healthy patients with ehrlichiosis, even without electrocardiographic or chemical evidence of myocarditis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/50\">",
"     50",
"    </a>",
"    ]. Pericardial effusion leading to tamponade has also been reported but is uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/51\">",
"     51",
"    </a>",
"    ]. A single case report exists of a child with E. chaffeensis infection who developed clinical manifestations of hemophagocytic lymphohistiocytosis, which resolved with treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HGA infection can be complicated by serious and even fatal opportunistic infections, including herpes simplex esophagitis, invasive aspergillosis, and candidiasis. In addition, a septic or toxic shock-like illness may occur in patients with severe HGA and HME infections [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/32,53\">",
"     32,53",
"    </a>",
"    ]. Postinfectious complications such as demyelinating polyneuropathy and brachial plexopathy have been temporally linked with HGA infections [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/54,55\">",
"     54,55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical and epidemiologic features of both HGA and HME overlap with those of Rocky Mountain spotted fever (RMSF), often making it difficult to distinguish between these disorders (",
"    <a class=\"graphic graphic_table graphicRef50677 \" href=\"UTD.htm?19/42/20141\">",
"     table 2",
"    </a>",
"    ). Ehrlichiosis has been called \"spotless\" RMSF [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/48\">",
"     48",
"    </a>",
"    ], but this appellation is misleading, as infection due to R. rickettsii can be \"spotless\" as well. Nevertheless, the combination of no rash and leukopenia makes ehrlichial infection more likely. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=see_link\">",
"     \"Clinical manifestations and diagnosis of Rocky Mountain spotted fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ehrlichiosis may also be confused with viral illnesses (such as mononucleosis, Colorado tick fever, West Nile virus infection), thrombotic thrombocytopenic purpura, hematologic malignancy, cholangitis, the early phases of hepatitis A infection, and community acquired pneumonia. Leukopenia and thrombocytopenia may be erroneously attributed to drugs such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    or chemotherapy when ehrlichial infection occurs in patients with underlying hematological malignancies or HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/45,56\">",
"     45,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The diagnosis of HGA can be overlooked if there is simultaneous infection with B. burgdorferi [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/22\">",
"     22",
"    </a>",
"    ]. In such cases, the typical rash of early Lyme disease (erythema migrans) may mislead the clinician into ignoring possible co-infection with ehrlichiae. Findings that may suggest coinfection include leukopenia, thrombocytopenia, and high fever (all relatively uncommon in Lyme disease) and abnormal liver enzyme tests [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis is considerably broader in patients with subacute or chronic infection due to E. chaffeensis. In this setting, other zoonoses (such as tularemia and brucellosis) and lymphoma should be considered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Culture of ehrlichiae is extremely difficult. Until 1995, only two isolates of E. chaffeensis had been recovered from humans; in both cases, this process required over 30 days of cultivation [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/48\">",
"     48",
"    </a>",
"    ]. The isolation of A. phagocytophilum from three additional patients has been accomplished using a cell culture system derived from human promyelocytic leukemia cells [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23525?source=see_link\">",
"     \"Biology of ehrlichiae\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the absence of culture, other techniques have been used to establish the diagnosis of ehrlichiosis, including polymerase chain reaction (PCR) and immunologic and immunohistologic methods [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/4,48\">",
"     4,48",
"    </a>",
"    ]. At present, there are five primary methods available for the diagnosis of HME and HGA; the preferred and most widely available of these methods is the indirect fluorescent antibody (IFA) test:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serology using the indirect fluorescent antibody (IFA) test and reagents specific for HME and HGA or enzyme-linked immunosorbent assays (ELISA). ELISA tests are only qualitative and cannot be used to monitor changes in antibody titers.",
"     </li>",
"     <li>",
"      Examination of peripheral blood or buffy coat for the presence of characteristic intraleukocytic morulae.",
"     </li>",
"     <li>",
"      PCR for HME and HGA.",
"     </li>",
"     <li>",
"      Immunochemical staining of ehrlichial or anaplasmal antigens in tissue.",
"     </li>",
"     <li>",
"      Clinical diagnosis based upon synthesis of the history, clinical, and epidemiologic features of an individual case. As an example, the presence of a normal white blood cell and platelet count and the failure to detect morulae in white cells should NOT dissuade clinicians from considering HGA or HME as a possible diagnosis in patients with a nonspecific febrile illness who become ill in the spring or summer months and have a history of recent tick bite or tick exposure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;HME and HGA are separate diseases caused by different etiologic agents. As a result, serologic tests that detect E. chaffeensis, the cause of HME, will not detect the human granulocytic anaplasmosis and vice versa [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/48\">",
"     48",
"    </a>",
"    ]. Because serologic cross reactivity can occasionally occur between E. chaffeensis and A. phagocytophilum, it is not possible to reliably differentiate between these two infections with a single serologic assay [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/11,57\">",
"     11,57",
"    </a>",
"    ]. Most patients with E. ewingii infection develop antibodies that cross-react with E. chaffeensis antigens [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are no standardized antigens or consensus opinion as to what thresholds constitute a significant antibody titer. Thus, each laboratory relies on its own empirically derived cutoff point for a positive test result. Serologic tests for ehrlichiosis and anaplasmosis are available through most state public health and multiple commercial laboratories.",
"     </li>",
"     <li>",
"      HME and HGA can be confirmed serologically using the indirect fluorescent antibody (IFA) test. IFA tests can be obtained through state health departments. The current case definition of HME used by the CDC requires at least a fourfold rise or fall in immunofluorescent antibody titer against E. chaffeensis between the acute and convalescent stage with a minimum titer considered to be indicative of current or previous infection. In most laboratories, the minimum titer ranges from 1:64 to 1:80 [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/10\">",
"       10",
"      </a>",
"      ]. An important limitation of this test is that antibodies first become detectable two to three weeks after the onset of the illness [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/58\">",
"       58",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      The IFA test has been estimated to be 94 to 100 percent sensitive if the second paired sample is obtained 14 days following the onset of symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/59\">",
"       59",
"      </a>",
"      ]. Antibody titers may persist at high levels following infection; thus, caution must be exercised in interpreting a single positive convalescent antibody titer in an individual patient [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/60\">",
"       60",
"      </a>",
"      ]. Although specific IgM antibody tests for ehrlichiosis may become positive during the first six to seven weeks after onset, there are no data that suggest that such tests are more sensitive than standard IgG-based tests [",
"      <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/30\">",
"       30",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Buffy coat examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intracytoplasmic inclusions (morulae) are characteristic of ehrlichiosis [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/61\">",
"     61",
"    </a>",
"    ]. They are seen in the cytoplasm of neutrophils in 20 to 80 percent of patients with HGA and in mononuclear cells in a minority of HME patients (1 to 20 percent) (",
"    <a class=\"graphic graphic_picture graphicRef61249 graphicRef50113 \" href=\"UTD.htm?1/38/1642\">",
"     picture 1A-B",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/10,62,63\">",
"     10,62,63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of morulae has varied in different series of patients with HGA. One report found obvious morulae in the peripheral smear in 28 of 35 (80 percent) patients with laboratory-confirmed HGA infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/38\">",
"     38",
"    </a>",
"    ]. In a study of 141 patients with HGA from the upper Midwest and New York, 86 of 141 patients (61 percent) had morulae visualized in neutrophils [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/49\">",
"     49",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_picture graphicRef60471 \" href=\"UTD.htm?1/27/1459\">",
"     picture 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCR-based testing is available for both HME and HGA. While not yet standardized, these techniques are becoming more widely used for the diagnosis of ehrlichiosis and are available from the CDC and some state public health and commercial laboratories. Sensitivity and specificity of assays vary from laboratory to laboratory. The reported sensitivity of PCR for HGA varies from 60 to 70 percent; more variable results have been reported in studies of patients with HME (52 to 87 percent sensitivity) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Both nested PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/64\">",
"     64",
"    </a>",
"    ] and nested reverse transcription (RT)-PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/65\">",
"     65",
"    </a>",
"    ] based upon the 16S rRNA gene appear to be useful for the diagnosis of HME. In one study of 38 patients, the seven culture-confirmed cases of HME were also PCR-positive, and none of the 31 culture-negative patients, including six with RMSF, had a positive PCR from whole blood [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/64\">",
"     64",
"    </a>",
"    ]. For HGA, use of epank1 primers to the A. phagocytophilum genogroup seemed to enhance sensitivity over the 16S rRNA-based tests [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/66\">",
"     66",
"    </a>",
"    ]. Most clinicians use PCR in association with serologic tests for the diagnosis of ehrlichiosis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    therapy may decrease the sensitivity of nucleic acid detection assays [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Clinicians should be aware that PCR assays for E. chaffeensis and E. ewingii may not detect the ehrlichia species that was identified in patients from Wisconsin and Minnesota in 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/4\">",
"     4",
"    </a>",
"    ]. However, the ehrlichia-anaplasma real-time groEL PCR assay detects the DNA specific for this species and may be useful in a patient with a compatible illness and epidemiologic risk factors [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/4,67\">",
"     4,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Immunohistochemical stains",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few cases of ehrlichiosis and anaplasmosis have been diagnosed by staining bone marrow tissue or autopsy tissue such as spleen, lymph nodes, liver, or lung [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/68-70\">",
"     68-70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Due to the limitations of the other more definitive studies (limited sensitivity of blood smears and the time delay with serologic tests), the most practical method of diagnosis is by synthesis of individual clinical and epidemiologic features into a clinical diagnosis. Recognition of the clinical and laboratory features of HGA or HME in patients who reside in a geographic location where the disease is known to occur is usually sufficient. For example, a history of tick bite or tick exposure during the spring or summer months in a resident of an endemic area coupled with a febrile illness and the presence of leukopenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    thrombocytopenia provides strong circumstantial evidence for the diagnosis of ehrlichiosis and is sufficient justification for the initiation of therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no controlled trials examining the efficacy of antimicrobial therapy in either HME or HGA. Treatment recommendations are based on clinical case series and in vitro data. Both",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    appear to be effective clinically.",
"   </p>",
"   <p>",
"    In one study of 237 patients with HME, 3 of 49 outpatients (6.1 percent) treated only with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    required hospitalization compared with 35 of 38 patients (92 percent) treated only with antibiotics other than tetracycline or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/37\">",
"     37",
"    </a>",
"    ]. Among hospitalized patients, recovery was faster for those initially treated with tetracycline (median, 16 days) or chloramphenicol (median, 12 days) than for those initially treated with other antibiotics (median, 27 days); furthermore, severe illness or death was more probable in patients who did not receive tetracycline or chloramphenicol until eight days or more after the onset of symptoms (odds ratio 4.38; 95% CI 1.36-14.0). These clinical findings are different from those observed in vitro: E. chaffeensis is susceptible only to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , while chloramphenicol does not appear to be effective [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/71\">",
"     71",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is only a limited amount of retrospectively collected clinical data on the comparative efficacy of tetracyclines (most commonly",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    in the treatment of HME. In one study of hospitalized patients with this disorder, those treated with doxycycline defervesced one day sooner than those treated with chloramphenicol (two versus three days) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/36\">",
"     36",
"    </a>",
"    ]. Despite this minimal difference in clinical response, the in vitro data has led some experts to advise doxycycline as the treatment of choice (even in children) [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Similar results are seen in patients with HGA. In one study, for example, 2 of 12 patients died; the other 10 improved rapidly after the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    , with defervescence occurring within 48 hours after initiation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/72\">",
"     72",
"    </a>",
"    ]. In another report, all 18 patients with HGA who were treated with doxycycline had resolution of fever within 48 hours of starting therapy. The four patients with ehrlichiosis \"Ewingii\" due to E. ewingii also responded to treatment with doxycycline, including three receiving immunosuppressive therapy for other conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several pregnant women and children with A. phagocytophilum have been successfully treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , which has demonstrated in vitro activity [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/30,73\">",
"     30,73",
"    </a>",
"    ]. In contrast, relapse of infection has been described in a single patient with HGA infection treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/74\">",
"     74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some patients have a prolonged course and do not respond well to therapy. In a case report, persistent infection with E. chaffeensis was documented in a man who died 68 days after initial hospitalization for his acute illness [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/75\">",
"     75",
"    </a>",
"    ]. Despite treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/49/2840?source=see_link\">",
"     tetracycline",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    , E. chaffeensis morulae were found in samples of his bone marrow on day 18 and at post-mortem. (See",
"    <a class=\"local\" href=\"#H28\">",
"     'Morbidity and mortality'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The optimal duration of therapy is unknown. Seven to 10 days of therapy is commonly recommended and relapses have not been described with this treatment duration [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Recommended approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be initiated in all patients suspected of having ehrlichiosis or anaplasmosis. The drug of choice in all patients is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    . This is also the preferred therapy in RMSF, the disorder most frequently confused with ehrlichiosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14725?source=see_link\">",
"     \"Treatment of Rocky Mountain spotted fever\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     Doxycycline",
"    </a>",
"    can be given either orally or intravenously at a dose of 100 mg twice daily. We agree with published recommendations that doxycycline treatment for ehrlichiosis be continued in adults for 10 days or for three to five days after defervescence [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/27,44\">",
"     27,44",
"    </a>",
"    ]. This treatment course will also treat the possibility of coinfection with B. burgdorferi [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We do not use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/54/1897?source=see_link\">",
"     chloramphenicol",
"    </a>",
"    although there is no consensus on this issue. Chloramphenicol is also not available in most pharmacies in the United States.",
"   </p>",
"   <p>",
"    Patients who have intolerance or allergy to tetracyclines can be treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    (300 mg twice daily) for 7 to 10 days, but careful follow-up and monitoring of such patients is recommended, as there is only anecdotal information on the efficacy of this agent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one in vitro study,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/46/33504?source=see_link\">",
"     levofloxacin",
"    </a>",
"    (MIC ranging from 0.06 to 0.5",
"    <span class=\"nowrap\">",
"     mcg/mL)",
"    </span>",
"    was active against eight strains of A. phagocytophilum isolated from various geographic areas of the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/73\">",
"     73",
"    </a>",
"    ], but there is no clinical experience with this agent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Children",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children weighing more than 45 kg should receive the adult dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    ; smaller children should receive 4",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two divided doses (up to a maximum of 100 mg per dose).",
"   </p>",
"   <p>",
"    All tetracyclines can cause dental staining in children; however, the risk of such staining after use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is minimal if a short course of therapy is administered.",
"   </p>",
"   <p>",
"    Children &ge;8 years can be treated with a 10-day course of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    . For severely ill children &lt;8 years of age without concomitant Lyme disease, a treatment course of four to five days (or three days after resolution of fever) is recommended by the Infectious Disease Society of America guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/44\">",
"     44",
"    </a>",
"    ]. Careful follow-up and monitoring of children treated with this short course is recommended. If co-infection with Lyme disease is documented, then",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/10/42152?source=see_link\">",
"     amoxicillin",
"    </a>",
"    (50",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in three divided doses [maximum of 500 mg per dose]) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/61/26583?source=see_link\">",
"     cefuroxime",
"    </a>",
"    axetil (30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day in two divided doses [maximum of 500 mg per dose]) should be started at the end of the short course doxycycline treatment to complete a 14 day course of therapy.",
"   </p>",
"   <p>",
"    Successful treatment of HGA with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    in two children has been reported, but clinical experience is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/76\">",
"     76",
"    </a>",
"    ]. Rifampin therapy (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    twice per day, maximum 300 mg per dose) for 7 to 10 days can be given as an alternative, but children treated with rifampin should be carefully monitored to ensure clinical resolution of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/44\">",
"     44",
"    </a>",
"    ]. Children co-infected with B. burgdorferi should be treated with a complete course of treatment for erythema migrans, since rifampin is not effective for Lyme disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=see_link\">",
"     \"Treatment of Lyme disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;At present, no guidelines exist for the treatment of ehrlichiosis in pregnancy. Although",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is not recommended for use in pregnancy, some experts believe that, in cases when the infection is considered life-threatening, doxycycline might be warranted in the treatment of HME or HGA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/10\">",
"     10",
"    </a>",
"    ]. Doxycycline has been used successfully and safely in a few cases in pregnant women with HME or HGA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/46,77\">",
"     46,77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An alternative to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    , which is both active and bactericidal against HGA in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/78\">",
"     78",
"    </a>",
"    ]. Rifampin has been effective in small numbers of pregnant women with HGA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/46,79\">",
"     46,79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Perinatal transmission of HGA has only been described in case reports [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/29,46,80\">",
"     29,46,80",
"    </a>",
"    ]. Performing PCR on blood from the neonate should be considered in cases of HGA that were diagnosed in the mother during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Reinfection and immunity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Even without treatment most patients with ehrlichiosis probably make a full recovery, and currently there is no evidence that untreated ehrlichiosis produces chronic symptoms such as those seen after Lyme disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/15\">",
"     15",
"    </a>",
"    ]. However, infection may not confer long lasting immunity. A single patient has been reported who experienced two episodes of HGA spaced two years apart. At the onset of his second infection, his antibody titer to A. phagocytophilum had fallen from 1:1280 to 1:80 [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human ehrlichiosis is a serious disease with significant morbidity, particularly if appropriate antibiotics are delayed. In a 10-year retrospective review of 46 highly selected patients with confirmed Ehrlichia or Anaplasma infections seen at a tertiary care center, delay in",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    therapy was associated with increased rates of mechanical ventilation and longer hospital stays [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The limited available information on mortality is based upon small case series, which may overestimate mortality rates. Estimated mortality rates have been 2 to 5 percent for HME and as high as 7 to 10 percent for HGA [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/48\">",
"     48",
"    </a>",
"    ]. As an example, a retrospective case study of 41 patients with laboratory-diagnosed HGA infection found a case fatality rate of 4.9 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/38\">",
"     38",
"    </a>",
"    ]. Secondary opportunistic infections, such as fungal pneumonia, were common in patients who died [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/38\">",
"     38",
"    </a>",
"    ]. However, another report suggested that the fatality rate of HGA might actually be less than 1 percent given the frequency of asymptomatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ehrlichiosis may be a life-threatening infection in patients co-infected with HIV. In a review of 21 coinfected patients, 6 of 13 patients died, and several other patients had severe illnesses that included respiratory failure, gastrointestinal hemorrhage, and fungal superinfections [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Severe infection also occurs in solid organ transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/83,84\">",
"     83,84",
"    </a>",
"    ]. One report that reviewed 23 cases of ehrlichiosis in this population found that organ failure occurred in all patients and six patients (25 percent) died [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Outcomes data are more limited in children. In a review of 32 children with HME cited above, there were no deaths but three had significant neurologic deficits at discharge [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the fact that 5 to 15 percent of Lone Star ticks may be infected with E. chaffeensis and 10 to 50 percent of Ixodes scapularis ticks may be infected with A. phagocytophilum in endemic areas, preventive antibiotic therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    is",
"    <strong>",
"     NOT",
"    </strong>",
"    recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/10\">",
"     10",
"    </a>",
"    ]. Rather, patients with tick bites should be told to report any symptoms compatible with infection in the two weeks following a bite.",
"   </p>",
"   <p>",
"    The use of tick repellants such as DEET (N,N-diethyl-3-methylbenzamide, previously called N,N-diethyl-m-toluamide) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"     permethrin",
"    </a>",
"    and a prompt examination and removal of ticks, if found, after exposure to tick-infested environments, remain the only practical preventive measures as there are no licensed vaccines for ehrlichiosis or anaplasmosis. Animal studies suggest that it may take 24 to 48 hours following tick attachment to transmit A. phagocytophilum infection [",
"    <a class=\"abstract\" href=\"UTD.htm?6/5/6234/abstract/85\">",
"     85",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=see_link\">",
"     \"Prevention of arthropod and insect bites: Repellents and other measures\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The two most important human ehrlichial diseases are human monocytic ehrlichiosis (HME), which is caused by Ehrlichia chaffeensis, and human granulocytic anaplasmosis (HGA), which is caused by Anaplasma phagocytophilum. Most cases occur in the spring and summer, and in the United States, cases of HGA outnumber HME. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The principal vector of E. chaffeensis (agent of HME) is the Lone Star tick (Amblyomma americanum) (",
"      <a class=\"graphic graphic_picture graphicRef71086 \" href=\"UTD.htm?23/1/23582\">",
"       picture 3",
"      </a>",
"      ). The vectors of A. phagocytophilum (agent of HGA) are Ixodes scapularis (",
"      <a class=\"graphic graphic_picture graphicRef73802 \" href=\"UTD.htm?14/13/14558\">",
"       picture 4",
"      </a>",
"      ) in the eastern United States and I. pacificus (",
"      <a class=\"graphic graphic_picture graphicRef60501 \" href=\"UTD.htm?26/25/27038\">",
"       picture 5",
"      </a>",
"      ) in the western United States. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Tick vectors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both forms of ehrlichiosis typically present as an acute illness with an incubation period of one to two weeks. Most patients are febrile, with nonspecific symptoms such as malaise, myalgia, headache, and chills. One feature that may distinguish HME from HGA is a rash, which is present in about 30 percent of patients with HME but is rare in patients with HGA (",
"      <a class=\"graphic graphic_table graphicRef50677 \" href=\"UTD.htm?19/42/20141\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most common laboratory abnormalities in patients with HME and HGA, occurring in 50 to 90 percent of patients, are leukopenia, thrombocytopenia, and elevated plasma levels of aminotransferases (transaminases). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical and epidemiologic features of both HGA and HME overlap with those of Rocky Mountain spotted fever (RMSF), often making it difficult to distinguish between these three disorders (",
"      <a class=\"graphic graphic_table graphicRef50677 \" href=\"UTD.htm?19/42/20141\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred and most widely available diagnostic method for ehrlichiosis is the indirect fluorescent antibody (IFA) test. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treatment should be initiated in all patients suspected of having ehrlichiosis or anaplasmosis. We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      as the drug of choice in all nonpregnant patients (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Recommended approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      in pregnant patients when the infection is considered life-threatening (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Estimated mortality rates are 2 to 5 percent for HME and as high as 7 to 10 percent for HGA. However, these rates are almost certainly overestimates, since many patients have subclinical illness. (See",
"      <a class=\"local\" href=\"#H28\">",
"       'Morbidity and mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In areas where tick borne pathogens other than ehrlichiosis are not a consideration, we suggest that patients with tick bites not be treated with prophylactic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Preventive measures include the use of tick repellants such as DEET (N,N-diethyl-3-methylbenzamide) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/22/28004?source=see_link\">",
"       permethrin",
"      </a>",
"      and a prompt examination and removal of ticks, if found, after exposure to tick-infested environments. (See",
"      <a class=\"local\" href=\"#H29\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/1\">",
"      Maeda K, Markowitz N, Hawley RC, et al. Human infection with Ehrlichia canis, a leukocytic rickettsia. N Engl J Med 1987; 316:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/2\">",
"      Chen SM, Dumler JS, Bakken JS, Walker DH. Identification of a granulocytotropic Ehrlichia species as the etiologic agent of human disease. J Clin Microbiol 1994; 32:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/3\">",
"      Buller RS, Arens M, Hmiel SP, et al. Ehrlichia ewingii, a newly recognized agent of human ehrlichiosis. N Engl J Med 1999; 341:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/4\">",
"      Pritt BS, Sloan LM, Johnson DK, et al. Emergence of a new pathogenic Ehrlichia species, Wisconsin and Minnesota, 2009. N Engl J Med 2011; 365:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/5\">",
"      Dumler JS, Barbet AF, Bekker CP, et al. Reorganization of genera in the families Rickettsiaceae and Anaplasmataceae in the order Rickettsiales: unification of some species of Ehrlichia with Anaplasma, Cowdria with Ehrlichia and Ehrlichia with Neorickettsia, descriptions of six new species combinations and designation of Ehrlichia equi and 'HGE agent' as subjective synonyms of Ehrlichia phagocytophila. Int J Syst Evol Microbiol 2001; 51:2145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/6\">",
"      Centers for Disease Control and Prevention (CDC). Summary of notifiable diseases--United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/7\">",
"      Gong&oacute;ra-Biachi RA, Zavala-Vel&aacute;zquez J, Castro-Sansores CJ, Gonz&aacute;lez-Mart&iacute;nez P. First case of human ehrlichiosis in Mexico. Emerg Infect Dis 1999; 5:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/8\">",
"      Mart&iacute;nez MC, Guti&eacute;rrez CN, Monger F, et al. Ehrlichia chaffeensis in child, Venezuela. Emerg Infect Dis 2008; 14:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/9\">",
"      Yabsley MJ. Natural history of Ehrlichia chaffeensis: vertebrate hosts and tick vectors from the United States and evidence for endemic transmission in other countries. Vet Parasitol 2010; 167:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/10\">",
"      Chapman AS, Bakken JS, Folk SM, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain spotted fever, ehrlichioses, and anaplasmosis--United States: a practical guide for physicians and other health-care and public health professionals. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/11\">",
"      Centers for Disease Control and Prevention (CDC). Anaplasmosis and ehrlichiosis - Maine, 2008. MMWR Morb Mortal Wkly Rep 2009; 58:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/12\">",
"      Fishbein DB, Kemp A, Dawson JE, et al. Human ehrlichiosis: prospective active surveillance in febrile hospitalized patients. J Infect Dis 1989; 160:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/13\">",
"      Standaert SM, Dawson JE, Schaffner W, et al. Ehrlichiosis in a golf-oriented retirement community. N Engl J Med 1995; 333:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/14\">",
"      Carpenter CF, Gandhi TK, Kong LK, et al. The incidence of ehrlichial and rickettsial infection in patients with unexplained fever and recent history of tick bite in central North Carolina. J Infect Dis 1999; 180:900.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/15\">",
"      Bakken JS, Dumler JS. Human granulocytic ehrlichiosis. Clin Infect Dis 2000; 31:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/16\">",
"      Dumler JS, Choi KS, Garcia-Garcia JC, et al. Human granulocytic anaplasmosis and Anaplasma phagocytophilum. Emerg Infect Dis 2005; 11:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/17\">",
"      Doudier B, Olano J, Parola P, Brouqui P. Factors contributing to emergence of Ehrlichia and Anaplasma spp. as human pathogens. Vet Parasitol 2010; 167:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/18\">",
"      Santino I, Cammarata E, Franco S, et al. Multicentric study of seroprevalence of Borrelia burgdorferi and Anaplasma phagocytophila in high-risk groups in regions of central and southern Italy. Int J Immunopathol Pharmacol 2004; 17:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/19\">",
"      Strle F. Human granulocytic ehrlichiosis in Europe. Int J Med Microbiol 2004; 293 Suppl 37:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/20\">",
"      Blanco JR, Oteo JA. Human granulocytic ehrlichiosis in Europe. Clin Microbiol Infect 2002; 8:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/21\">",
"      Paddock CD, Folk SM, Shore GM, et al. Infections with Ehrlichia chaffeensis and Ehrlichia ewingii in persons coinfected with human immunodeficiency virus. Clin Infect Dis 2001; 33:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/22\">",
"      Nadelman RB, Horowitz HW, Hsieh TC, et al. Simultaneous human granulocytic ehrlichiosis and Lyme borreliosis. N Engl J Med 1997; 337:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/23\">",
"      Schwartz I, Fish D, Daniels TJ. Prevalence of the rickettsial agent of human granulocytic ehrlichiosis in ticks from a hyperendemic focus of Lyme disease. N Engl J Med 1997; 337:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/24\">",
"      Belongia EA. Epidemiology and impact of coinfections acquired from Ixodes ticks. Vector Borne Zoonotic Dis 2002; 2:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/25\">",
"      Lockhart JM, Davidson WR, Stallknecht DE, et al. Isolation of Ehrlichia chaffeensis from wild white-tailed deer (Odocoileus virginianus) confirms their role as natural reservoir hosts. J Clin Microbiol 1997; 35:1681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/26\">",
"      Kocan AA, Levesque GC, Whitworth LC, et al. Naturally occurring Ehrlichia chaffeensis infection in coyotes from Oklahoma. Emerg Infect Dis 2000; 6:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/27\">",
"      Parola P, Raoult D. Ticks and tickborne bacterial diseases in humans: an emerging infectious threat. Clin Infect Dis 2001; 32:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/28\">",
"      Dugan VG, Little SE, Stallknecht DE, Beall AD. Natural infection of domestic goats with Ehrlichia chaffeensis. J Clin Microbiol 2000; 38:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/29\">",
"      Horowitz HW, Kilchevsky E, Haber S, et al. Perinatal transmission of the agent of human granulocytic ehrlichiosis. N Engl J Med 1998; 339:375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/30\">",
"      Bakken JS, Dumler S. Human granulocytic anaplasmosis. Infect Dis Clin North Am 2008; 22:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/31\">",
"      Bakken JS, Krueth JK, Lund T, et al. Exposure to deer blood may be a cause of human granulocytic ehrlichiosis. Clin Infect Dis 1996; 23:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/32\">",
"      Zhang L, Liu Y, Ni D, et al. Nosocomial transmission of human granulocytic anaplasmosis in China. JAMA 2008; 300:2263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/33\">",
"      Krause PJ, Wormser GP. Nosocomial transmission of human granulocytic anaplasmosis? JAMA 2008; 300:2308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/34\">",
"      Centers for Disease Control and Prevention (CDC). Anaplasma phagocytophilum transmitted through blood transfusion--Minnesota, 2007. MMWR Morb Mortal Wkly Rep 2008; 57:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/35\">",
"      Aguero-Rosenfeld ME, Horowitz HW, Wormser GP, et al. Human granulocytic ehrlichiosis: a case series from a medical center in New York State. Ann Intern Med 1996; 125:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/36\">",
"      Everett ED, Evans KA, Henry RB, McDonald G. Human ehrlichiosis in adults after tick exposure. Diagnosis using polymerase chain reaction. Ann Intern Med 1994; 120:730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/37\">",
"      Fishbein DB, Dawson JE, Robinson LE. Human ehrlichiosis in the United States, 1985 to 1990. Ann Intern Med 1994; 120:736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/38\">",
"      Bakken JS, Krueth J, Wilson-Nordskog C, et al. Clinical and laboratory characteristics of human granulocytic ehrlichiosis. JAMA 1996; 275:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/39\">",
"      Ratnasamy N, Everett ED, Roland WE, et al. Central nervous system manifestations of human ehrlichiosis. Clin Infect Dis 1996; 23:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/40\">",
"      Berry DS, Miller RS, Hooke JA, et al. Ehrlichial meningitis with cerebrospinal fluid morulae. Pediatr Infect Dis J 1999; 18:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/41\">",
"      Roland WE, McDonald G, Caldwell CW, Everett ED. Ehrlichiosis--a cause of prolonged fever. Clin Infect Dis 1995; 20:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/42\">",
"      Dumler JS, Bakken JS. Human granulocytic ehrlichiosis in Wisconsin and Minnesota: a frequent infection with the potential for persistence. J Infect Dis 1996; 173:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/43\">",
"      Schutze GE, Buckingham SC, Marshall GS, et al. Human monocytic ehrlichiosis in children. Pediatr Infect Dis J 2007; 26:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/44\">",
"      Wormser GP, Dattwyler RJ, Shapiro ED, et al. The clinical assessment, treatment, and prevention of lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2006; 43:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/45\">",
"      Esbenshade A, Esbenshade J, Domm J, et al. Severe ehrlichia infection in pediatric oncology and stem cell transplant patients. Pediatr Blood Cancer 2010; 54:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/46\">",
"      Dhand A, Nadelman RB, Aguero-Rosenfeld M, et al. Human granulocytic anaplasmosis during pregnancy: case series and literature review. Clin Infect Dis 2007; 45:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/47\">",
"      Muffly T, McCormick TC, Cook C, Wall J. Human granulocytic ehrlichiosis complicating early pregnancy. Infect Dis Obstet Gynecol 2008; 2008:359172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/48\">",
"      Dumler JS, Bakken JS. Ehrlichial diseases of humans: emerging tick-borne infections. Clin Infect Dis 1995; 20:1102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/49\">",
"      Bakken JS, Aguero-Rosenfeld ME, Tilden RL, et al. Serial measurements of hematologic counts during the active phase of human granulocytic ehrlichiosis. Clin Infect Dis 2001; 32:862.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/50\">",
"      Vanek NN, Kazi S, Cepero NM, et al. Human ehrlichiosis causing left ventricular dilatation and dysfunction. Clin Infect Dis 1996; 22:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/51\">",
"      Goodman JL, Nelson C, Vitale B, et al. Direct cultivation of the causative agent of human granulocytic ehrlichiosis. N Engl J Med 1996; 334:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/52\">",
"      Burns S, Saylors R, Mian A. Hemophagocytic lymphohistiocytosis secondary to Ehrlichia chaffeensis infection: a case report. J Pediatr Hematol Oncol 2010; 32:e142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/53\">",
"      Dumler JS. Anaplasma and Ehrlichia infection. Ann N Y Acad Sci 2005; 1063:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/54\">",
"      Bakken JS, Erlemeyer SA, Kanoff RJ, et al. Demyelinating polyneuropathy associated with human granulocytic ehrlichiosis. Clin Infect Dis 1998; 27:1323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/55\">",
"      Horowitz HW, Marks SJ, Weintraub M, Dumler JS. Brachial plexopathy associated with human granulocytic ehrlichiosis. Neurology 1996; 46:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/56\">",
"      Brantley RK. Trimethoprim-sulfamethoxazole and fulminant ehrlichiosis. Pediatr Infect Dis J 2001; 20:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/57\">",
"      Comer JA, Nicholson WL, Olson JG, Childs JE. Serologic testing for human granulocytic ehrlichiosis at a national referral center. J Clin Microbiol 1999; 37:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/58\">",
"      Dawson JE, Fishbein DB, Eng TR, et al. Diagnosis of human ehrlichiosis with the indirect fluorescent antibody test: kinetics and specificity. J Infect Dis 1990; 162:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/59\">",
"      Brouqui P, Bacellar F, Baranton G, et al. Guidelines for the diagnosis of tick-borne bacterial diseases in Europe. Clin Microbiol Infect 2004; 10:1108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/60\">",
"      Bakken JS, Haller I, Riddell D, et al. The serological response of patients infected with the agent of human granulocytic ehrlichiosis. Clin Infect Dis 2002; 34:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/61\">",
"      Dumler JS, Madigan JE, Pusterla N, Bakken JS. Ehrlichioses in humans: epidemiology, clinical presentation, diagnosis, and treatment. Clin Infect Dis 2007; 45 Suppl 1:S45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/62\">",
"      Bakken JS, Dumler JS. Ehrlichiosis and anaplasmosis. Infect Med 2004; 21:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/63\">",
"      Paddock CD, Childs JE. Ehrlichia chaffeensis: a prototypical emerging pathogen. Clin Microbiol Rev 2003; 16:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/64\">",
"      Standaert SM, Yu T, Scott MA, et al. Primary isolation of Ehrlichia chaffeensis from patients with febrile illnesses: clinical and molecular characteristics. J Infect Dis 2000; 181:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/65\">",
"      Felek S, Unver A, Stich RW, Rikihisa Y. Sensitive detection of Ehrlichia chaffeensis in cell culture, blood, and tick specimens by reverse transcription-PCR. J Clin Microbiol 2001; 39:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/66\">",
"      Walls JJ, Caturegli P, Bakken JS, et al. Improved sensitivity of PCR for diagnosis of human granulocytic ehrlichiosis using epank1 genes of Ehrlichia phagocytophila-group ehrlichiae. J Clin Microbiol 2000; 38:354.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/67\">",
"      Bell CA, Patel R. A real-time combined polymerase chain reaction assay for the rapid detection and differentiation of Anaplasma phagocytophilum, Ehrlichia chaffeensis, and Ehrlichia ewingii. Diagn Microbiol Infect Dis 2005; 53:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/68\">",
"      Dawson JE, Paddock CD, Warner CK, et al. Tissue diagnosis of Ehrlichia chaffeensis in patients with fatal ehrlichiosis by use of immunohistochemistry, in situ hybridization, and polymerase chain reaction. Am J Trop Med Hyg 2001; 65:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/69\">",
"      Dumler JS, Dawson JE, Walker DH. Human ehrlichiosis: hematopathology and immunohistologic detection of Ehrlichia chaffeensis. Hum Pathol 1993; 24:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/70\">",
"      Marty AM, Dumler JS, Imes G, et al. Ehrlichiosis mimicking thrombotic thrombocytopenic purpura. Case report and pathological correlation. Hum Pathol 1995; 26:920.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/71\">",
"      Brouqui P, Raoult D. In vitro antibiotic susceptibility of the newly recognized agent of ehrlichiosis in humans, Ehrlichia chaffeensis. Antimicrob Agents Chemother 1992; 36:2799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/72\">",
"      Bakken JS, Dumler JS, Chen SM, et al. Human granulocytic ehrlichiosis in the upper Midwest United States. A new species emerging? JAMA 1994; 272:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/73\">",
"      Maurin M, Bakken JS, Dumler JS. Antibiotic susceptibilities of Anaplasma (Ehrlichia) phagocytophilum strains from various geographic areas in the United States. Antimicrob Agents Chemother 2003; 47:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/74\">",
"      Wormser GP, Filozov A, Telford SR 3rd, et al. Dissociation between inhibition and killing by levofloxacin in human granulocytic anaplasmosis. Vector Borne Zoonotic Dis 2006; 6:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/75\">",
"      Dumler JS, Sutker WL, Walker DH. Persistent infection with Ehrlichia chaffeensis. Clin Infect Dis 1993; 17:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/76\">",
"      Krause PJ, Corrow CL, Bakken JS. Successful treatment of human granulocytic ehrlichiosis in children using rifampin. Pediatrics 2003; 112:e252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/77\">",
"      Smith Sehdev AE, Sehdev PS, Jacobs R, Dumler JS. Human monocytic ehrlichiosis presenting as acute appendicitis during pregnancy. Clin Infect Dis 2002; 35:e99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/78\">",
"      Klein MB, Nelson CM, Goodman JL. Antibiotic susceptibility of the newly cultivated agent of human granulocytic ehrlichiosis: promising activity of quinolones and rifamycins. Antimicrob Agents Chemother 1997; 41:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/79\">",
"      Buitrago MI, Ijdo JW, Rinaudo P, et al. Human granulocytic ehrlichiosis during pregnancy treated successfully with rifampin. Clin Infect Dis 1998; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/80\">",
"      Casau NC, Hewins ME, Zaleznik DF. Treatment of human granulocytic ehrlichiosis during pregnancy and risk of perinatal transmission. Scand J Infect Dis 2002; 34:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/81\">",
"      Horowitz HW, Aguero-Rosenfeld M, Dumler JS, et al. Reinfection with the agent of human granulocytic ehrlichiosis. Ann Intern Med 1998; 129:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/82\">",
"      Hamburg BJ, Storch GA, Micek ST, Kollef MH. The importance of early treatment with doxycycline in human ehrlichiosis. Medicine (Baltimore) 2008; 87:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/83\">",
"      Safdar N, Love RB, Maki DG. Severe Ehrlichia chaffeensis infection in a lung transplant recipient: a review of ehrlichiosis in the immunocompromised patient. Emerg Infect Dis 2002; 8:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/84\">",
"      Tan HP, Dumler JS, Maley WR, et al. Human monocytic ehrlichiosis: an emerging pathogen in transplantation. Transplantation 2001; 71:1678.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?6/5/6234/abstract/85\">",
"      des Vignes F, Piesman J, Heffernan R, et al. Effect of tick removal on transmission of Borrelia burgdorferi and Ehrlichia phagocytophila by Ixodes scapularis nymphs. J Infect Dis 2001; 183:773.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7907 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-E943584887-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6234=[""].join("\n");
var outline_f6_5_6234=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H30\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MICROBIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Human monocytic ehrlichiosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Human granulocytic anaplasmosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      E. ewingii infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TICK VECTORS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      ANIMAL RESERVOIRS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Other modes of transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Special hosts",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Buffy coat examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Immunohistochemical stains",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Recommended approach",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Children",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Reinfection and immunity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7907\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7907|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/48/24323\" title=\"figure 1\">",
"      HGA annual incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?26/28/27078\" title=\"figure 2\">",
"      Distribution vector ticks",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7907|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?13/1/13334\" title=\"picture 1A\">",
"      Intracellular HME EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?24/43/25269\" title=\"picture 1B\">",
"      HGE in neutrophil EM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?17/31/17906\" title=\"picture 2\">",
"      Wright Giemsa stain morula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/1/23582\" title=\"picture 3\">",
"      Lone star tick",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/13/14558\" title=\"picture 4\">",
"      Ixodes scapularis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?26/25/27038\" title=\"picture 5\">",
"      Ixodes pacificus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?1/27/1459\" title=\"picture 6\">",
"      Anaplasmosis peripheral smear",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7907|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/42/19115\" title=\"table 1\">",
"      Epidemiology of ehrlichiosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?19/42/20141\" title=\"table 2\">",
"      Features of tickborne infx",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/62/23525?source=related_link\">",
"      Biology of ehrlichiae",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/51/14135?source=related_link\">",
"      Clinical manifestations and diagnosis of Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/1/43031?source=related_link\">",
"      Prevention of arthropod and insect bites: Repellents and other measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/54/27498?source=related_link\">",
"      Treatment of Lyme disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/24/14725?source=related_link\">",
"      Treatment of Rocky Mountain spotted fever",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f6_5_6235="Criteria for essential tremor";
var content_f6_5_6235=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F62078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F62078&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Criteria for diagnosis of essential tremor",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Core criteria",
"       </td>",
"       <td class=\"subtitle1\">",
"        Secondary criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bilateral action tremor of the hands and forearms (but not rest tremor)",
"       </td>",
"       <td>",
"        Long duration (&gt;3 years)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Absence of other neurologic signs, with the exception of cogwheel phenomenon",
"       </td>",
"       <td>",
"        Positive family history",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        May have isolated head tremor with no signs of dystonia",
"       </td>",
"       <td>",
"        Beneficial response to alcohol",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permisssion from: Bain P, Brin M, Deuschl G, et al. Criteria for the diagnosis of essential tremor. Neurology 2000; 54(suppl 4):s7. Copyright &copy; 2000 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6235=[""].join("\n");
var outline_f6_5_6235=null;
var title_f6_5_6236="ACC AHA Rx bioprosthetic valve";
var content_f6_5_6236=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75489&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Antithrombotic therapy in patients with bioprosthetic heart valves",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\" colspan=\"1\">",
"       Class I - There is evidence and/or general agreement that antithrombotic therapy is indicated in patients with bioprosthetic heart valves in the following settings:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       &bull;  Warfarin to achieve a goal INR of 2.0 to 3.0 after:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1. Aortic valve replacement (AVR) if risk factors* are present.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2. MVR with a bioprosthesis if risk factors* are present.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1_start\">",
"       &bull;  Role of aspirin:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       1. After AVR or MVR with no risk factors* at a dose of 75 to 100 mg/day",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       2. After AVR or MVR in patients with risk factors* who cannot take warfarin, at a dose of 75 to 325 mg/day.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"sublist1\">",
"       3. In addition to warfarin, in patients with risk factors* at a dose of 75 to 100 mg/day.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Class IIa - The weight of evidence or opinion is in favor of the usefulness of antithrombotic therapy in patients with bioprosthetic heart valves in the following setting:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td colspan=\"1\">",
"       &bull;  In the first three months after AVR or MVR in patients with no risk factors*, warfarin to achieve a goal INR of 2.0 to 3.0.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Risk factors include atrial fibrillation, prior thromboembolism, severe left ventricular dysfunction (ejection fraction less than 0.30), and a hypercoagulable state.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118:e523.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6236=[""].join("\n");
var outline_f6_5_6236=null;
var title_f6_5_6237="Geriatric trauma risks";
var content_f6_5_6237=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F80367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F80367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Potential pitfalls in the management of the elderly trauma patient",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        What the injured elderly would tell you (if they could)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Related physiology and rationale",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"I can go from normotensive to hypotensive in a heartbeat.\"",
"       </td>",
"       <td>",
"        Profound, life-threatening hypovolemia may occur in the setting of normal blood pressure. Physiologic reserve is minimal, and hemodynamic decompensation can occur quickly.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"I respond poorly to too much or too little fluid.\"",
"       </td>",
"       <td>",
"        The therapeutic window for cardiac preload is narrow, and inadequate preload monitoring may lead to errors in volume resuscitation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"My subdural hematoma hasn't expanded enough yet to really affect my level of consciousness.\"",
"       </td>",
"       <td>",
"        Cortical atrophy, common in the elderly, may act to delay the clinical manifestations of serious intracranial hemorrhage. This hemorrhage may be clinically occult.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Trauma is not really my major problem.\"",
"       </td>",
"       <td>",
"        Stroke, myocardial infarction, and seizures may result from falls or motor vehicle crashes and delayed diagnosis of the principal underlying problem.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"I only look like I have adequate ventilatory reserve.\"",
"       </td>",
"       <td>",
"        Ventilatory failure and respiratory arrest may occur suddenly in conjunction with chest or abdominal injuries despite a benign outward clinical appearance.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"I get demand ischemia if I have too much pain or my hematocrit drops below 29.\"",
"       </td>",
"       <td>",
"        Myocardial (demand) ischemia may result from severe or prolonged pain or from transfusion thresholds that have not been appropriately liberalized in the setting of coronary artery disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"I can't stand even a little shock or hypoxia...and neither can my myocardium.\"",
"       </td>",
"       <td>",
"        Even minor perturbations in perfusion, oxygenation, or vasoconstriction may lead to major cardiac complications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"My connective tissue just ain't what it used to be...\"",
"       </td>",
"       <td>",
"        Decrease in connective tissue integrity with less \"tamponade effect\" for hemorrhage into soft tissues. Blood loss into soft tissue spaces, including subcutaneous loss, may be excessive and is often overlooked.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"The sensitivity of my abdominal examination is better than flipping a coin...but not much.\"",
"       </td>",
"       <td>",
"        Clinical manifestations of serious abdominal injury in elderly patients are often minimal. Reliance on the abdominal examination often leads to missed abdominal injuries.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"My bones are brittle...my hip bone, my shin bone, and my aortic bone!\"",
"       </td>",
"       <td>",
"        BAI may occur in the elderly in the absence of conventional signs or symptoms. A low threshold for CT imaging should exist.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"A little medication goes a long way with me...\"",
"       </td>",
"       <td>",
"        Failure to adjust medication dosage, particularly sedative-hypnotics and analgesics, may result in serious complications.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"I just haven't been eating so well lately.\"",
"       </td>",
"       <td>",
"        Chronic malnutrition is common and often undiagnosed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"My injuries weren't accidental.\"",
"       </td>",
"       <td>",
"        Elder abuse is common and often unreported and undiagnosed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        \"Major trauma? Heck, I wouldn't even tolerate a brisk haircut...\"",
"       </td>",
"       <td>",
"        Underestimating and undermanaging comorbidities (eg, chronic obstructive pulmonary disease, coronary artery disease, smoking, ethyl alcohol [ETOH] consumption) may result in preventable morbidity/mortality.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Mackersie, RC. Pitfalls in the evaluation and resuscitation of the trauma patient. Emerg Med Clin North Am 2010; 28:1. Illustration used with the permission of Elsevier Inc. All rights reserved.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6237=[""].join("\n");
var outline_f6_5_6237=null;
var title_f6_5_6238="Distribution of Crohns disease";
var content_f6_5_6238=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Distribution of Crohn's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 250px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Approximate frequency of ileal and colonic involvement in Crohn's disease. Crohn's disease can involve the entire gastrointestinal tract from mouth to perianal area.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of the American Gastroenterological Association&copy;. This slide cannot be downloaded but may be purchased as part of a set from the AGA through Milner-Fenwick, Inc at 1- 800-432-8433.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6238=[""].join("\n");
var outline_f6_5_6238=null;
var title_f6_5_6239="PUV VUR urine extravasation";
var content_f6_5_6239=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F75302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F75302&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Urine extraction observed in a voiding cystourethrogram in a patient with posterior urethal valves",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 327px; height: 385px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Voiding cystourethrogram of a&nbsp;patient with severe urethral obstruction secondary to posterior urethral valves with&nbsp;high grade vesicoureteral&nbsp;reflux&nbsp;and urinary extravasation from kidney (white arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Nicholas Holmes, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f6_5_6239=[""].join("\n");
var outline_f6_5_6239=null;
